Cyclodextrin composition encapsulating selective ATP inhibitor and its application

By encapsulating 3-halogenated pyruvate within cyclodextrin, the stability and toxicity issues during systemic administration were resolved, enabling effective antitumor therapy.

CN115054698BActive Publication Date: 2024-11-08JOHNS HOPKINS UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210378454.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2014-05-13
Filing Date
2015-01-14
Publication Date
2024-11-08
Estimated Expiration
2035-01-14

AI Technical Summary

Technical Problem

Existing selective ATP inhibitors, such as 3-halopyruvate, are susceptible to water and nucleophilic environments during systemic administration, resulting in poor stability and increased toxicity, which limits their application in systemic therapy.

Method used

Encapsulating 3-halogenated pyruvate within cyclodextrin provides stable release and maintains the half-life of the compound in vivo by protecting the halogen moiety from aqueous and nucleophilic environments.

Benefits of technology

It improved the in vivo stability of 3-halopyruvic acid and reduced systemic toxicity, maintaining its antitumor effect and achieving effective systemic administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 31721
    Figure 31721
  • Figure 35330
    Figure 35330
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention provides a composition comprising cyclodextrin encapsulating a selective ATP inhibitor, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims the benefit of priority to U.S. Provisional Application No. 61 / 927,259, filed on January 14, 2014, and U.S. Provisional Application No. 61 / 992,572, filed on May 13, 2014, which are incorporated herein by reference. Background of the Invention

[0003] The knowledge that cancer cells depend on increased glycolysis rather than oxidative phosphorylation for survival is known as the "Warburg hypothesis" (Warburg (1956) Science 123:309-314). This concept forms the basis for using glycolysis and its related enzymes as unique targets for the development of new anticancer therapeutics (Shaw (2006) Curr. Opin. Cell Biol. 18:598-608; Gatenby and Gillies (2007) Biochem. Cell Biol. 39:1358-1366). One such drug is 3-bromopyruvic acid (3-BrPA), a synthetic brominated derivative of pyruvic acid that acts as an irreversible inhibitor of glycolysis (Ko et al. (2001) Cancer Lett. 173:83-91; Geschwind et al. (2002) Cancer Res. 62:3909-3913). It affects energy metabolism by targeting the glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Ganapathy-Kanniappan et al. (2009) AntiCancer Res. 29:4909-4918). In addition, the anticancer effects of 3-BrPA were consistent and reproducible in vitro and in vivo against multiple tumor models. A variety of tumors have been shown to be sensitive to 3-BrPA treatment, including, for example, liver cancer (Geschwind et al. (2002) Cancer Res. 62:3909-30913; Vali et al. (2007) J. Vasc. Interv. Radiol. 18:95-101; and Ganapathy-Kanniappan et al. (2012) Radiology 262:834-845), pancreatic cancer (Cao et al. (2008) Clin. Cancer Res. 14:1831-1839; Bhardwaj et al. (2010) AntiCancer Res. 30:743-749; and Ota et al. (2013) Target Oncol. 8:145-151), brain tumors (El Sayed et al. (2012) J. Bioenerg. Biomembr.44:61-79; Davidescu et al. (2012) J. Bioenerg. Biomembr. 44:51-60) and breast cancer (Buijs et al. (2013) J. Vasc. Interv. Radiol. 24:737-743). In conclusion, the inhibition of GAPDH and the molecular specificity of 3-BrPA have been established, and targeting tumor glycolysis via 3-BrPA may be a feasible strategy for the treatment of cancer, especially solid malignancies (Ganapathy-Kanniappan et al. (2012) Oncotarget 3:940-95; Ganapathy-Kanniappan et al. (2013) AntiCancer Res. 33:13-20).

[0004] Despite the potential for therapeutic applications of selective ATP inhibitors, such as 3-halopyruvic acids like 3-BrPA, however, several factors have hampered the development of systemically administered formulations. For example, the alkylating (chemical) nature of 3-halopyruvic acids and related compounds renders them extremely reactive with electrophilic molecules, which generally requires increased dosages, which has the negative effect of increasing toxicity, particularly increasing alkylation near the injection site. In particular, the presence of water or any nucleophilic groups commonly found in proteins, such as amino or sulfhydryl groups, chemically inactivates the compounds. Likewise, the in vivo stability of such compounds is affected by a number of factors including glutathione, NADH and other reducing molecules in the blood and circulatory system. Therefore, it is important to keep these compounds free from such factors, at least until the first cycle through.

[0005] Although it is recognized that protecting selective ATP inhibitors, such as 3-halopyruvic acids like 3-BrPA, until they are delivered to an organ or tissue is crucial for their antitumor effects under systemic delivery, many approaches to achieve such protection, such as encapsulating them in liposomes, microspheres, nanospheres, nanoparticles, vacuoles, etc., have not been successful. For example, molecules such as 3-BrPA are known to undesirably rapidly extravasate from PEGylated liposomes or react with proteins such as albumin in albumin-based nanoparticles. Although sporadic reports have documented intraperitoneal delivery of 3-BrPA in preclinical models, the efficacy and dosing regimens are very limited. Due to these failures, 3-BrPA therapy is currently relegated to local regional delivery (e.g., percutaneous ablation, intra-arterial delivery, and intratumoral injection) rather than systemic delivery (Kunjithapatham et al. (2013) BMC Res. Notes 6: 277).

[0006] Therefore, there is a great need in the art to identify compositions of selective ATP inhibitors, such as 3-halopyruvic acids like 3-BrPA, suitable for systemic administration. SUMMARY OF THE INVENTION

[0007] The present invention is based, in part, on the discovery that encapsulating a selective inhibitor of ATP production, such as 3-halopyruvic acid (e.g., 3-BrPA), within a cyclodextrin: a) stabilizes the alkylating agent in vivo by protecting the halogen moiety from aqueous and nucleophilic environments that would render the compound ineffective, and b) provides steady release of the compound necessary to maintain a reasonable half-life of the compound in vivo.

[0008] In one aspect, a composition is provided comprising a cyclodextrin and a drug represented by the following general formula: , wherein each independently occurs: X represents a halide, a sulfonate, a carboxylate, an alkoxide, or an amine oxide; R1 represents OR, H, N(R")2, a C1-C6 alkyl, a C6-C12 aryl, a C1-C6 heteroalkyl, or a C6-C12 heteroaryl; R" represents H, a C1-C6 alkyl, or a C6-C12 aryl; R represents H, an alkali metal, a C1-C6 alkyl, a C6-C12 aryl, or C(O)R'; and R' represents H, a C1-C20 alkyl, or a C6-C12 aryl, wherein the cyclodextrin encapsulates the drug. In one embodiment, at least one hydroxyl chemical group of at least one α-D-pyranoglucoside unit of the cyclodextrin is replaced with an ionizable chemical group. In another embodiment, at least one hydroxyl chemical group of at least one α-D-pyranoglucoside unit is selected from C2, C3, and C6 hydroxyl chemical groups. In yet another embodiment, the C2, C3 and C6 hydroxyl chemical groups of at least one α-D-pyranoglucoside unit of the cyclodextrin are replaced with ionizable chemical groups. In yet another embodiment, at least one α-D-pyranoglucoside unit of the cyclodextrin is selected from 2, 3, 4, 5, 6, 7, 8, and all α-D-pyranoglucoside units of the cyclodextrin. In another embodiment, the ionizable chemical group is the same at all substituted positions. In yet another embodiment, the ionizable chemical group is a weakly basic functional group or a weakly acidic functional group. For example, the weakly basic functional group (X) may have a CH3-X - A pK between 6.5 and 8.5 a Or the weakly acidic functional group (Y) may have a pK between 4.0 and 6.5 based on CH3-Y a In yet another embodiment, the weakly basic or weakly acidic functional group is selected from the group consisting of amino, ethylenediamino, dimethylethylenediamino, dimethylphenylamino, dimethylnaphthylamino, succinyl, carboxyl, sulfonyl, and sulfate functional groups. In another embodiment, the cyclodextrin has a pK between 4.0 and 8.5. a1. In yet another embodiment, the composition is a liquid or solid pharmaceutical formulation. In yet another embodiment, the drug is uncharged or hydrophobic. In another embodiment, the cyclodextrin is selected from β-cyclodextrin, α-cyclodextrin, and γ-cyclodextrin. In yet another embodiment, the cyclodextrin is β-cyclodextrin. In yet another embodiment, the drug is 3-halopyruvic acid. In another embodiment, the drug is 3-bromopyruvic acid. In yet another embodiment, the composition is formulated for systemic administration. In yet another embodiment, the composition further comprises an anti-cancer therapeutic agent.

[0009] In another aspect, a kit comprising a composition described herein, and instructions for use is provided.

[0010] In yet another aspect, a method for treating a subject with cancer is provided, comprising administering to the subject a therapeutically effective amount of a composition described herein. In one embodiment, the composition is administered systemically. In another embodiment, systemic administration is selected from oral, intravenous, intraperitoneal, subcutaneous, and intramuscular administration. In yet another embodiment, the subject is treated with at least one additional anti-cancer therapy. In yet another embodiment, at least one additional anti-cancer therapy is radiation therapy. In another embodiment, the cancer is a solid tumor. In yet another embodiment, the cancer is selected from liver cancer, pancreatic cancer, lung cancer, and breast cancer. In yet another embodiment, the cancer is liver cancer. In another embodiment, the subject is a mammal. In yet another embodiment, the mammal is a human. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 The chemical structure and ring topology of the β-cyclodextrin molecule are shown (see, e.g., Rasheed et al. (2008) Sci. Pharm. 76: 567-598).

[0012] Figure 2 A-2B shows the effects of 3-BrPA or β-CD-3-BrPA on MiaPaCa2 cells ( Figure 2 A) and Suit-2 cells ( Figure 2 B) impact.

[0013] Figure 3 Shown are the effects of 3-BrPA or β-CD-3-BrPA on MiaPaCa2 cells after 72 h of treatment.

[0014] Figure 4 The effect of β-CD-3-BrPA on tumor growth in vivo is shown.

[0015] Figure 5 Complete tumor response was shown in 3 mice treated with β-CD-3-BrPA.

[0016] Figure 6 Display as Figure 4 and 5 Histopathological analysis of orthotopic MiaPaCa-2 tumors treated with

[0017] Figure 7 Results of NMR spectroscopy are shown. The enlarged inset shows the upfield shift (0.1 ppm) of the methylene protons observed upon complexation of β-CD-3-BrPA.

[0018] Figure 8 Killing curves for 2D and 3D organotypic cell cultures based on luminescence-based cell viability are shown in MiaPaCa-2 (upper row) and Suit-2 (middle row) cells. Cells were cultured under normoxic and hypoxic conditions for 72 hours and then exposed to 3-bromopyruvic acid (3-BrPA), 1:1-β-cyclodextrin (CD)-3-BrPA, or β-CD alone as a control for 24 hours. Cells were cultured for 24 hours and then treated with gemcitabine for 72 hours. For 3D organotypic cell cultures (lower row), luc MiaPaCa-2 cells were cultured under normoxic or hypoxic conditions for a total of 6 days. Single treatment with 3-BrPA or β-CD-3-BrPA was performed on day 5 for 24 hours. Exposure to gemcitabine began on day 3 for 72 hours. Bioluminescence imaging was performed on day 6 to evaluate drug penetration and effects on cell viability. The lower right frame contains an immuno-blot for HIF-1α to confirm the presence of hypoxia.

[0019] Fig. 9 Demonstrating the role of 3-bromopyruvate in 3D organotypic cell culture. Homogeneous embedding of collagen I matrix luc MiaPaCa-2 cells were confirmed by confocal optical microscopy (day 1). 3D organotypic cell cultures were cultured under normoxic conditions and treated with 3-BrPA every other day for a total of three times. Phase contrast microscopy and bioluminescence imaging (the latter only for MiaPaCa-2 cells) were performed on day 6 to evaluate the effects on cell morphology and viability. Immunofluorescence staining of F-actin and cleaved caspase-3 was performed in frozen sections of 3D organotypic cell cultures. DAPI was used as a nucleic acid counterstain.

[0020] Fig.10Show further effects of 3-bromopyruvic acid in 3D organotypic cell culture. Suit-2 cells uniformly embedded in collagen I-matrix were confirmed by confocal optical microscopy (day 1). 3D organotypic cell cultures were cultured under normoxic conditions and treated with 3-BrPA every other day for a total of three times. Phase contrast microscopy and bioluminescence imaging (the latter only for MiaPaCa-2 cells) were performed on day 6 to evaluate the effects on cell morphology and viability. Immunofluorescence staining of F-actin and cleaved caspase-3 was performed in frozen sections of 3D organotypic cell cultures. DAPI was used as a nucleic acid counterstain.

[0021] Fig.11 A-11D shows the effect of 3-bromopyruvate on cell invasiveness. MiaPaCa-2 ( Fig.11 A) and Suit-2( Fig.11 B) Cells were seeded into Boyden invasion chambers. Overnight culture was followed by treatment with 3-bromopyruvic acid for 48 hours (MiaPaCa-2) or 72 hours (Suit-2). Invading cells on the membrane bottom side of the invasion insert were stained using Giemsa-like staining. Images show invaded cells at 4x, 10x, and 20x magnification. Relative quantification of invasion was calculated by measuring the area of ​​stained cells in the full field of view at 10x. MMP-9 activity and secretion were measured in concentrated supernatants of MiaPaCa-2 and Suit-2 cells by zymography ( Fig.11 C) and Western blotting ( Fig.11 D) Assay. (*) indicates statistical significance (p-value < 0.05).

[0022] Fig.12 A-12D showed the in vivo efficacy of β-cyclodextrin-3-bromopyruvate. A total of 1.5 x 10 6 indivual luc MiaPaCa-2 cells were orthotopically implanted into a total of 42 male nude mice. After 1 week of xenograft growth, tumors were confirmed using bioluminescence imaging (BLI). A representative number of animals is shown in Fig.12 A. Animals were randomized to receive β-CD-3-BrPA (N = 21), free 3-BrPA (N = 7), gemcitabine (N = 7), and β-CD (N = 7). Animals were imaged weekly over the course of 28 days. The overall progression of signal is shown in Fig.12 B. According to Kaplan-Meier analysis, animals treated with free 3-BrPA showed excessive treatment-related toxicity, resulting in the loss of 5 / 7 animals at the end of the experiment, so that a statistically relevant number did not survive to be included in the final image analysis ( Fig.12C). The vehicle-control (β-CD) did not show any treatment-related toxicity and was inert when administered intraperitoneally ( Fig.12 C). At the completion of the experiment, all animals were sacrificed and exploratory necropsies were performed to extract organs and evaluate potential lesions. For β-CD-3-BrPA, when compared to inert vehicle ( Fig.12 D), no organ toxicity (tissue effects) was observed.

[0023] Fig.13 Ex vivo pathological and immunohistochemical tumor analysis is shown. H&E staining of tumors treated with β-CD, gemcitabine, or β-CD-3-BrPA (3 representative tumors are shown) demonstrates the therapeutic effect of β-CD-3-BrPA. The squares within the H&E-stained whole-tumor overview indicate areas magnified for further analysis of the anti-tumor effect of the drug, which was confirmed by staining for cleaved caspase-3 and Ki67. In addition, a significant reduction in GAPDH, a major target of 3-BrPA, and MCT-1, a specific transporter, was determined. DETAILED DESCRIPTION OF THE INVENTION

[0024] It has been determined herein that cyclodextrins can encapsulate selective inhibitors of ATP production such as 3-halopyruvic acid (e.g., 3-BrPA) to stabilize the alkylating compound in an aqueous environment, as well as reduce the ability of nucleophilic entities in proteins to access it, thereby reducing its systemic toxicity and maintaining its alkylating ability. Such compositions have been demonstrated herein in multiple in vitro cell lines, using different forms of cyclodextrin (e.g., β and α) and different ratios of active agent encapsulation relative to cyclodextrin, and in vivo animal tumor models. For example, such compositions have been shown herein to maintain the functional characteristics of selective inhibitors of ATP production in killing cancer cells in vitro and in vivo, such that for systemic administration, their activity can be preserved and protected until it reaches the target tissue, organ, and / or tumor, while minimizing toxicity. This determination is unexpected because cyclodextrins are known to have a destabilizing effect on many compounds through direct catalytic effects, particularly increasing pH (Rasheed et al. (2008) Sci. Pharm.76: 567-598). While it would have been expected that this catalytic effect of cyclodextrins would be great for 3-halopyruvic acids (since they are halogenated derivatives of pyruvic acid), it was surprisingly determined that cyclodextrins actually protect and stabilize 3-BrPA. It was also surprisingly determined that cyclodextrins modified by replacing one or more hydroxyl groups on one or more of their α-D-pyranoglucoside units with ionizable groups that produce a negative charge (anion) stabilize 3-halopyruvic acid better than those cyclodextrins having ionizable groups that produce a positive charge (cation) or unmodified cyclodextrins, such as unmodified α- or β-cyclodextrins. Without being bound by theory, it is believed that the anionic moiety on the cyclodextrin forces the halogen atom (e.g., bromine) of the halopyruvic acid (e.g., 3-BrPA) to sit in the cavity. It was also surprisingly determined that β-cyclodextrin encapsulates 3-BrPA in a form that protects and stabilizes 3-BrPA, particularly significantly better than α-cyclodextrin in terms of in vivo efficacy and also in vitro efficacy.

[0025] Thus, the present invention provides compositions and kits comprising such 3-halopyruvate compounds encapsulated in cyclodextrins, and methods of making and using such compositions and kits.

[0026] A. Definition

[0027] In order to more readily understand the present invention, certain terms and phrases are defined below and throughout the specification.

[0028] The articles "a" and "an" are used herein to refer to one or more than one (ie, at least one) of the grammatical objects of an object. For example, "an element" means one element or more than one element.

[0029] The term "3-bromopyruvate" or "3-BrPA" refers to 3-bromopyruvate, analogs and derivatives of 3-bromopyruvate, prodrugs of 3-bromopyruvate, metabolites of 3-bromopyruvate, and salts thereof.

[0030] The term "administering" means providing a drug or composition to a subject, and includes, but is not limited to, administration by a medical professional and self-administration.

[0031] The term "cancer" includes, but is not limited to, solid tumors and blood-borne tumors. The term cancer includes diseases of the skin, tissues, organs, bones, cartilage, blood, and blood vessels. The term "cancer" also includes primary and metastatic cancers.

[0032] The term "inhibit" or "inhibits" means to reduce, inhibit, attenuate, weaken, prevent, or stabilize the development or progression of a disease, disorder, or condition, the activity of a biological pathway, or a biological activity, such as the growth of a solid malignancy, for example, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or even 100%, as compared to an untreated control subject, cell, biological pathway, or biological activity or as compared to a target, such as the growth of a solid malignancy in a subject prior to treatment of the subject. By the term "reduce" is meant to inhibit, suppress, attenuate, weaken, prevent, or stabilize the symptoms of a cancer disease, disorder, or condition. It should be appreciated that, although not excluded, treatment of a disease, disorder, or condition does not require that the disease, disorder, condition, or symptoms associated therewith be completely eliminated.

[0033] The term "modulate" refers to upregulation (ie, activation or stimulation), downregulation (ie, inhibition or prevention), or a combination or separation of a response.

[0034] The term "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0035] The term "pharmaceutically-acceptable carrier" is used herein to refer to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or part of the body to another organ, or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can be used as pharmaceutically-acceptable carriers include: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) Pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffers; (21) polyesters, polycarbonates and / or polyanhydrides; and (22) other non-toxic compatible substances used in pharmaceutical formulations.

[0036] The term "pharmaceutically-acceptable salts" refers to the relatively non-toxic, inorganic and organic salts of compounds.

[0037] "Subjects" may include human subjects for medical purposes, such as for the treatment of existing diseases, disorders, conditions or for preventive treatment to prevent the occurrence of diseases, disorders or conditions, or animal subjects for medical, veterinary purposes, or development purposes. Suitable animal subjects include mammals, including, but not limited to, primates, such as humans, monkeys, apes, gibbons, chimpanzees, orangutans, macaques, etc.; cattle, such as cattle, bulls, etc.; sheep, such as sheep, etc.; goats, such as goats, etc.; pigs, such as piglets, boars, etc.; horses, such as horses, donkeys, zebras, etc.; felines, including wild cats and domestic cats; canines, including dogs; lagomorphs, including rabbits, hares, etc.; and rodents, including mice, rats, guinea pigs, etc. The animal may be a transgenic animal. In some embodiments, the subject is a human, including, but not limited to, a fetus, a newborn, an infant, a teenager, and an adult subject. In addition, "subjects" may include patients suffering from or suspected of having a disease, disorder or condition. Therefore, the terms "subject" and "patient" may be used interchangeably herein. The subject also includes animal disease models (eg, rats or mice used in experiments, etc.).

[0038] The terms "prevent," "preventing," "suppression," "prophylactic treatment," and the like refer to reducing the likelihood of developing a disease, disorder, or condition in a subject who is not suffering from but is at risk of or susceptible to developing the disease, disorder, or condition.

[0039] The term "subject suspected of having a disease" means a subject that exhibits one or more clinical signs of a disease or condition. In certain embodiments, the disease or condition is cancer. In certain embodiments, the cancer is leukemia or lymphoma.

[0040] The term "subject in need thereof" means a subject identified as being in need of medical treatment or therapy.

[0041] The terms "systemic administration," "systemic administration," "peripheral administration," and "peripheral administration" mean administration of a compound, drug, or other material (other than directly into the central nervous system) so that it enters the patient's system and thereby undergoes metabolism and other similar processes, e.g., subcutaneous administration.

[0042] The term "therapeutic agent" or "drug" refers to an agent that can produce a desired biological effect on a host. Chemotherapeutic agents and genotoxic agents are examples of therapeutic agents, which are substances of commonly known chemical origin, rather than biological substances, or produce therapeutic effects through specific mechanisms of action, respectively. Examples of therapeutic agents of biological origin include growth factors, hormones, and cytokines. Various therapeutic agents are known in the art and can be identified by their effects. Certain therapeutic agents can regulate erythrocyte proliferation and differentiation. Examples include chemotherapeutic nucleotides, drugs, hormones, non-specific (e.g., non-antibody) proteins, oligonucleotides (e.g., antisense oligonucleotides that bind to a target nucleic acid sequence (e.g., an mRNA sequence)), peptides, and peptidomimetics.

[0043] The term "therapeutic effect" refers to a local or systemic effect caused by a pharmacologically active substance in an animal, particularly a mammal, and more particularly in a human. The term therefore refers to any substance intended to be used for diagnosing, curing, alleviating, treating or preventing a disease in an animal or human, or for improving the desired physical or mental development and state. The phrase "therapeutically effective amount" means the amount of such a substance that produces some desired local or systemic effect with a reasonable benefit / risk ratio applicable to any treatment. In certain embodiments, the therapeutically effective amount of a compound will depend on its therapeutic index, solubility, etc. For example, certain compounds found by the method of the present invention can be given in sufficient amounts to produce a reasonable benefit / risk ratio applicable to such treatment.

[0044] As used herein, the terms "therapeutically effective amount" and "effective amount" mean an amount of a compound, material, or composition comprising a compound of the invention that is effective for producing some desired therapeutic effect in at least a subset of cells in an animal, at a reasonable benefit / risk ratio applicable to any medical treatment.

[0045] The term "treating" a disease in a subject or "treating" a subject having a disease refers to subjecting the subject to drug therapy, eg, administering a drug, such that at least one symptom of the disease is alleviated or prevented from worsening.

[0046] The term "tumor", "solid malignant tumor" or "neoplasm" refers to a lesion formed by abnormal or uncontrolled growth of cells. Preferably, the tumor is a malignant tumor, such as a malignant tumor formed by cancer.

[0047] B. Cyclodextrin

[0048] The term "cyclodextrin" refers to a family of cyclic oligosaccharides composed of 5 or more α-D-pyranoglucoside units linked together by C1-C4 bonds having a ring topology in which the larger and smaller openings of the ring structure expose certain hydroxyl groups of the α-D-pyranoglucoside units to the surrounding environment (e.g., solvent) (see, e.g. Figure 1 The term "inert cyclodextrin" refers to a cyclodextrin having the basic formula C6H 12 Cyclodextrins are cyclodextrins having 0.6 α-D-pyranoglucoside units and without any additional chemically substituted glucose structures (e.g., α-cyclodextrin with 6 glucose monomers, β-cyclodextrin with 7 glucose monomers, and γ-cyclodextrin with 8 glucose monomers). The term "cyclodextrin internal phase" refers to the relatively less hydrophilic region contained within (i.e., encapsulated within) the ring-shaped topology of the cyclodextrin structure. The term "cyclodextrin external phase" refers to the region not surrounded by the ring-shaped topology of the cyclodextrin structure and may include, for example, the aqueous environment present during systemic in vivo administration or refers to the internal phase of the structure that self-encapsulates the selective ATP production inhibitor / cyclodextrin complex. Cyclodextrins are used to solubilize hydrophobic components (see, e.g., Albers and Muller (1995) Crit. Rev. Therap. Drug Carrier Syst. 12:311-337; Zhang and Ma (2013) Adv. Drug Delivery Rev. 65:1215-1233; Laza-Knoerr et al. (2010) J. Drug Targ. 18:645-656; Challa et al. (2005) AAPS PharmSci. Tech. 6:E329-357; Uekama et al. (1998) Chem. Rev. 98:2045-2076; Szejtli (1998) Chem. Rev.98: 1743-1754; Stella and He (2008) Toxicol. Pathol. 36:30-42; Rajewski and Stella (1996) J. Pharm. Sci. 85:1142-1169; Thompson (1997) Crit. Rev. Therap. Drug Carrier Sys. 14:1-104; and Irie and Uekama (1997) J. Pharm. Sci. 86:147-162). Any material located within the cyclodextrin inner phase is considered "encapsulated".

[0049] As used herein, cyclodextrins according to the present invention are useful as long as the cyclodextrin can encapsulate the selective ATP production inhibitor. In some embodiments, the cyclodextrin also carries ionizable (e.g., weakly basic and / or weakly acidic) functional groups to improve the stability of the selective ATP production inhibitor. By protecting the stability of the selective ATP production inhibitor, it is meant that the selective ATP production inhibitor / cyclodextrin complex makes the selective ATP production inhibitor molecule more stable, as shown by the light stability, shelf life stability, thermal stability, stability against intramolecular cyclization, stability against acid hydrolysis, stability against general degradation, etc. compared to the stability of the selective ATP production inhibitor molecule not complexed with cyclodextrin.

[0050] In order to encapsulate the required therapeutic agent, cyclodextrin can be selected and / or chemically modified according to the characteristics of the required therapeutic agent and the parameters that are effectively and highly-loaded therein at a high concentration. For example, it is preferred that cyclodextrin itself has a high solubility in water to promote the loading of therapeutic agents, such as 3-halopyruvic acid. In some embodiments, the water solubility of cyclodextrin is at least 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL or higher. The water-soluble method realizing such an improvement is well known in the art.

[0051] In some embodiments, a large association constant with the therapeutic agent is preferred and can be obtained by selecting the number of glucose units in the cyclodextrin based on the size of the therapeutic agent (see, e.g., Albers and Muller (1995)). Crit. Rev. Therap. Drug Carrier Syst. 12:311-337; Stella and He (2008) Toxicol. Pathol. 36:30-42; and Rajewski and Stella (1996) J. Pharm. Sci.85:1142-1169). As a result, the solubility (nominal solubility) of the therapeutic agent can be further improved in the presence of cyclodextrin. For example, the association constant of cyclodextrin with the therapeutic agent can be 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, or more.

[0052] Derivatives formed by reacting with cyclodextrin hydroxyl groups (e.g., those hydroxyl groups lining the upper and lower ridges of the inert cyclodextrin torus) can be readily prepared and provide a method for modifying the physicochemical properties of the parent (inert) cyclodextrin. In some embodiments, the physicochemical properties of inert cyclodextrin molecules or cyclodextrin molecules that are not complexed with a selective ATP production inhibitor are different from the properties of cyclodextrin molecules complexed with a selective ATP production inhibitor. Therefore, the selective ATP production inhibitor molecules complexed with cyclodextrin can be identified by observing changes in solubility, chemical reactivity, UV / VIS absorbance, drug retention, chemical stability, etc. For example, it has been determined herein that modified hydroxyl groups, such as those facing away from the cyclodextrin internal phase, can be replaced with ionizable chemical groups to facilitate the loading of therapeutic agents, such as poorly soluble or hydrophobic drugs in modified cyclodextrins and their stabilization. In one embodiment, a modified cyclodextrin having at least one hydroxyl group substituted with an ionizable chemical group will result in a charged portion under certain solvent (e.g., pH) conditions. The term "charged cyclodextrin" refers to a cyclodextrin having one or more hydroxyl groups substituted with a charged moiety and a charge-carrying moiety. Such a moiety itself may be a charged group or it may comprise an organic moiety (e.g., a C1-C6 alkyl or C1-C6 alkyl ether moiety) substituted with one or more charged moieties.

[0053] In one embodiment, the "ionizable" or "charged" moiety is weakly ionizable. Weakly ionizable moieties are those that are either weakly basic or weakly acidic. Weakly basic functional groups (X) have a pK between about 6.0-9.0, 6.5-8.5, 7.0-8.0, 7.5-8.0, and any ranges included therein, based on CH3-X. a Similarly, the weakly acidic functional group (Y) has a log dissociation constant (pK) based on CH3-Y between about 3.0-7.0, 4.0-6.5, 4.5-6.5, 5.0-6.0, 5.0-5.5, and any ranges included therein. a). The pKa parameter is a well-known measure of the acid / base properties of a substance, and methods of pKa determination are traditional and conventional in the art. For example, the pKa values ​​of many weak acids are tabulated in reference books of chemistry and pharmacology. See, for example, IUPAC Handbook of Pharmaceutical Salts, edited by P. H. Stahl and C. G. Wermuth, Wiley-VCH, 2002; CRC Handbook of Chemistry and Physics, 82nd edition, edited by D. R. De, CRC Press, Florida, 2001, p. 8-44 to 8-56. Because cyclodextrins with more than one ionizable group have the pKa of the second and subsequent groups each indicated by a subscript.

[0054] Representative anionic moieties include, without limitation, succinyl, carboxylate, carboxymethyl, sulfonyl, phosphate, sulfoalkyl ether, sulfate, carbonate, thiocarbonate, thiocarbonate, phosphate, phosphonate, sulfonate, nitrate, and borate groups.

[0055] Representative cationic moieties include, but are not limited to, amino, guanidine, and quaternary ammonium groups.

[0056] In another embodiment, the modified cyclodextrin is a "polyanion" or a "polycation." A polyanion is a modified cyclodextrin with more than one negatively charged group resulting in a net negative ionic charge of more than two units. A polycation is a modified cyclodextrin with more than one positively charged group resulting in a net cationic charge of more than two units.

[0057] In another embodiment, the modified cyclodextrin is a "chargeable amphiphile". By "chargeable" is meant an amphiphile having a pK in the range of pH 4 to pH 8 or 8.5. Thus a chargeable amphiphile can be a weak acid or a weak base. By "amphoteric" is meant here a modified cyclodextrin having ionizable groups having both anionic and cationic properties, wherein: 1) at least one, and optionally both, of the cationic and anionic amphiphiles are chargeable, having at least one charged group having a pK between 4 and 8 to 8.5, 2) the cationic charge is preferably at pH 4, and 3) the anionic charge is preferably at pH 8-8.5.

[0058] In some embodiments, the "ionizable" or "charged" cyclodextrin as a whole, whether polyionic, amphiphilic, or otherwise, is weakly ionizable (i.e., having a pKa1 between about 4.0-8.5, 4.5-8.0, 5.0-7.5, 5.5-7.0, 6.0-6.5, and any range subsumed therein).

[0059] Any, some or all of the hydroxyl groups of any, some or all of the α-D-pyranoglucoside units of the cyclodextrin may be modified to ionizable chemical groups as described herein. Since the individual cyclodextrin hydroxyl groups differ in chemical reactivity, reaction with the modifying moiety may produce an amorphous mixture of positional and optical isomers. Alternatively, certain chemistries may allow pre-modified α-D-pyranoglucoside units to react to form a uniform product.

[0060] The total substitution that occurs is described by a term called the degree of substitution. For example, a 6-ethylenediamino-β-cyclodextrin with a degree of substitution of 7 will consist of a distribution of isomers of 6-ethylenediamino-β-cyclodextrin, wherein the average number of ethylenediamino groups per 6-ethylenediamino-β-cyclodextrin molecule is 7. The degree of substitution can be determined by mass spectrometry or nuclear magnetic resonance spectroscopy. In theory, the maximum degree of substitution is 18 for α-cyclodextrin, 21 for β-cyclodextrin, and 24 for γ-cyclodextrin, however, the substituents with hydroxyl groups themselves have the possibility of alkylating additional hydroxyl groups. The degree of substitution can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or more and can include complete substitution.

[0061] Another parameter is the stereochemical positioning of a given hydroxyl substitution. In one embodiment, at least one hydroxyl facing away from the interior of the cyclodextrin is substituted with an ionizable chemical group. For example, at least one α-D-glucopyranoside unit has C2, C3, C6, C2 and C3, C2 and C6, C3 and C6, and all three of the C2-C3-C6 hydroxyl groups substituted with ionizable chemical groups. Such carbon positions are well known in the art. For example, at least one α-D-glucopyranoside unit has C2, C3, C6, C2 and C3, C2 and C6, C3 and C6, and all three of the C2-C3-C6 hydroxyl groups substituted with ionizable chemical groups. Figure 1 The CH2OH moiety shown in represents the C6 carbon. Any such combination of hydroxyl groups can be similarly combined with at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, up to all of the α-D-pyranoglucoside units of the modified cyclodextrin and with any degree of substitution described herein.

[0062] It is also acceptable to incorporate one or more of the cyclodextrins described herein.

[0063] C. Selective inhibitors of ATP production and related compounds

[0064] Some embodiments of the present invention relate to the encapsulation of selective inhibitors of ATP production within cyclodextrins. The term "selective inhibitor of ATP production" refers to an antimetabolite agent (e.g., GAPDH inhibitors such as 3-halopyruvic acid like 3-bromopyruvic acid) that inhibits ATP production by interfering with the enzymatic process that generates ATP. In some embodiments, the selective inhibitor of ATP production is an "anti-tumor alkylating agent," which refers to a drug used in cancer treatment that causes the replacement of hydrogen with an alkyl group. As used herein, the term "alkyl" refers to a C 1-20 The term "alkyl" refers to a hydrocarbon group which is a linear (i.e., "straight chain"), branched, or cyclic, saturated or at least partially and in some cases fully unsaturated (i.e., alkenyl and alkynyl) hydrocarbon group containing between 1 and 20 carbon atoms by the removal of a single hydrogen atom. Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, iso-pentyl, neopentyl, n-butyl, iso-pentyl, tert-butyl, tert-butyl, tert-pentyl ... The term "branched" refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain. "Lower alkyl" refers to a alkyl group having 1 to about 8 carbon atoms (i.e., C 1-8 "Higher alkyl" refers to an alkyl group having about 10 to about 20 carbon atoms, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. In certain embodiments, "alkyl" refers specifically to a C 1-8 In other embodiments, "alkyl" refers in particular to C 1-8 Branched chain alkyl.

[0065] The alkyl group may be optionally substituted with one or more alkyl substituents ("substituted alkyl"), which may be the same or different. The term "alkyl substituent" includes, but is not limited to, alkyl, substituted alkyl, halo, arylamino, acyl, hydroxy, aryloxy, alkoxy, alkylthio, arylthio, aralkyloxy, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl. One or more oxygen, sulfur, or substituted or unsubstituted nitrogen atoms may be optionally inserted along the alkyl chain, wherein the nitrogen substituent is hydrogen, lower alkyl (also referred to herein as "alkylaminoalkyl"), or aryl. Thus, as used herein, the term "substituted alkyl" includes alkyl groups as defined herein, wherein one or more atoms or functional groups of the alkyl group are replaced with another atom or functional group, including, for example, alkyl, substituted alkyl, halo, aryl, substituted aryl, alkoxy, hydroxy, nitro, amino, alkylamino, dialkylamino, sulfate, and thiol.

[0066] In one embodiment, the selective inhibitor of ATP production is generally represented by the formula:

[0067]

[0068] Wherein X represents halide, sulfonate, carboxylate, alkoxide or amine oxide. In certain embodiments, X is selected from the following halide: fluoride, bromide, chloride and iodide. In one embodiment, the inhibitor is 3-halogenated pyruvic acid. In certain other embodiments, 3-halogenated pyruvic acid is selected from: 3-fluoropyruvic acid, 3-chloropyruvic acid, 3-bromopyruvic acid and 3-iodopyruvic acid. In one embodiment, 3-halogenated pyruvic acid is 3-bromopyruvic acid. In other embodiments, X is sulfonate and can be selected from: trifluoromethanesulfonate, mesylate and tosylate. In another embodiment, X is amine oxide such as dimethylamine oxide. In certain embodiments, R1 represents OR, H, N(R")2, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, or C6-C12 heteroaryl. Independently, in other embodiments, R" represents H, C1-C6 alkyl, or C6-C12 aryl. Independently, in still other embodiments, R represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl, or C(O)R'; and R' represents H, C1-C20 alkyl, or C6-C12 aryl.

[0069] In a preferred embodiment, the present invention also provides an inhibitor of ATP production represented by the following general formula:

[0070] X-CH2-CO-COOH,

[0071] Wherein X represents halide, sulfonate, carboxylate, alkoxide or amine oxide. In certain embodiments, X is halide and can be selected from: fluoride, bromide, chloride and iodide. In one embodiment, inhibitor is 3-halogenated pyruvic acid. In certain embodiments, 3-halogenated pyruvic acid is selected from: 3-fluoropyruvic acid, 3-chloropyruvic acid, 3-bromopyruvic acid and 3-iodopyruvic acid. In one embodiment, 3-halogenated pyruvic acid is 3-bromopyruvic acid. In other embodiments, X is selected from following sulfonate: trifluoromethanesulfonate, mesylate and tosylate. In another embodiment, X is amine oxide such as dimethylamine oxide.

[0072] Other analogs, derivatives, prodrugs, metabolites and salts thereof of 3-bromopyruvic acid may also be used, as long as these compounds or compositions have statistically similar anticancer effects to 3-bromopyruvic acid. When the present invention refers to treatment with 3-bromopyruvic acid, it should be understood that treatment may also be carried out with analogs, derivatives, prodrugs, metabolites and salts of 3-bromopyruvic acid, where applicable.

[0073] D. Cyclodextrin / ATP inhibitor combination

[0074] The present invention provides pharmaceutical compositions comprising the selective inhibitors of ATP production described above encapsulated in inert and / or modified cyclodextrins. Such complexes are referred to herein as cyclodextrin / ATP inhibitor compositions. The ratio of the selective inhibitor of ATP production to the cyclodextrin can be 1:1, so that one inhibitor molecule forms a complex with one cyclodextrin molecule. Alternatively, the ratio can be 2:1, 3:1, 4:1, 5:1, or more.

[0075] In one aspect, the present invention provides a pharmaceutically acceptable composition comprising a therapeutically effective amount of one or more such cyclodextrin / ATP inhibitors as described above formulated with one or more pharmaceutically acceptable carriers (additives) and / or diluents. In another aspect, the composition can be administered as is or mixed with a pharmaceutically acceptable carrier and can also be administered in combination with other anti-cancer therapies, such as chemotherapeutic agents, scavenger compounds, radiotherapy, biological therapy, etc. Therefore, the combination therapy includes sequential, simultaneous and separate, or co-administration of the composition, wherein the therapeutic effect of the first administration has not completely disappeared when the subsequent compound is administered.

[0076] As described in detail below, the pharmaceutical compositions of the present invention can be specially formulated for administration in solid or liquid form, including those suitable for the following routes of administration: (1) oral administration, for example, oral drenches (aqueous or non-aqueous solutions or suspensions) / tablets, for example, those for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes applied to the tongue; (2) parenteral administration, for example, subcutaneous, intramuscular, intravenous or intradural injection as, for example, sterile solutions or suspensions, or sustained release formulations; (3) topical application, for example, as a cream, ointment, or controlled release patch or spray applied to the skin; (4) intravaginal or rectal, for example, as a vaginal suppository, cream or foam; (5) sublingual; (6) intraocular; (7) transdermal; or (8) nasal.

[0077] As mentioned above, certain embodiments of the selective ATP inhibitor or cyclodextrin / ATP inhibitor composition may contain basic functional groups, such as amino or alkylamino groups, and thus be able to form pharmaceutically acceptable salts with pharmaceutically acceptable acids. These salts can be prepared in situ during administration of the medium or preparation of the dosage form, or by reacting the purified compound of the invention in its free base form with a suitable organic or inorganic acid, respectively, and separating the salt so formed during subsequent purification. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, mesylate, glucoheptonate, lactobionate, and dodecylsulfonate, etc. (see, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).

[0078] Pharmaceutically acceptable salts of the present compounds include, for example, conventional nontoxic salts or quaternary ammonium salts of compounds derived from non-toxic organic or inorganic acids. For example, such conventional nontoxic salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, aminosulfonic acid, phosphoric acid, nitric acid, etc.; and salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, isothionic acid, etc.

[0079] In other cases, the selective ATP inhibitor or cyclodextrin / ATP inhibitor composition of the present invention may contain one or more acidic functional groups and, therefore, be able to form pharmaceutically acceptable salts with pharmaceutically acceptable bases. These salts can also be prepared in situ during administration of the medium or preparation of the dosage form, or by reacting the purified compound in its free acid form with a suitable base, such as a pharmaceutically acceptable hydroxide, carbonate or bicarbonate of a metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representative alkali metal or alkaline earth metal salts include lithium, sodium, potassium, calcium, magnesium, and aluminum salts, etc. Representative organic amines useful for forming base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, etc. (see, for example, Berge et al., supra).

[0080] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

[0081] Examples of pharmaceutically-acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxytoluene (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, etc.; and (3) metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.

[0082] Cyclodextrin / ATP inhibitor composition preparations include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and / or parenteral administration. The preparation can be conveniently present in unit dosage form and can be prepared by any method known in the pharmaceutical field. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary according to the host to be treated and the specific mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be the amount of the compound that produces the therapeutic effect.

[0083] In certain embodiments, formulations of cyclodextrin / ATP inhibitor compositions may include other carriers to allow for greater stability, different in vivo release characteristics, targeting to specific sites, or any other desired characteristics that will allow for more effective delivery of the complex to a subject or target within a subject, such as, but not limited to, liposomes, microspheres, nanospheres, nanoparticles, vacuoles, micelle formers, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides. In certain embodiments, the foregoing formulations confer oral bioavailability to the compounds of the invention.

[0084] Liquid dosage formulations of cyclodextrin / ATP inhibitor compositions include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage form may contain inert diluents commonly used in the art, for example, water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (particularly, cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuran methanol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.

[0085] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0086] Suspensions, in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0087] Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as a lozenge (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and / or as a mouthwash, etc., each containing a predetermined amount of the active ingredient. The cyclodextrin / ATP inhibitor compositions of the present invention may also be administered as a bolus, electuary, or paste.

[0088] In solid dosage forms (e.g., capsules, tablets, pills, dragees, powders, granules, etc.), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and / or acarbamide; (3) humectants, such as glycerol; (4) disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarders, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol, glyceryl monostearate, and non-ionic surfactants; (8) absorbents, such as kaolin and bentonite; (9) Lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the composition may also contain a buffer. Solid components of a similar type may also be used as fillers in soft and hard-shell gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like.

[0089] Tablets can be made by compression or molding, optionally with one or more auxiliary ingredients. Compressed tablets can be prepared using a binder (e.g., gelatin or hydroxypropylmethylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), a surfactant or a dispersant. Molded tablets can be made by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine.

[0090] Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the art of pharmaceutical formulation. They may also be formulated to provide slow or controlled release of the active ingredient, using, for example, hydroxypropylmethylcellulose (to provide the desired release characteristics), other polymer matrices, liposomes and / or microspheres in varying proportions. The composition may also be formulated for rapid release, for example, freeze drying. They may be sterilized by, for example, filtering through a bacterial filter, or by combining a sterilizing agent in the form of a sterile solid composition that is soluble in sterile water, or some other sterile injectable medium used prior to use. These compositions may also optionally contain opacifiers and may have a composition that releases the active ingredient only (or preferably) in certain parts of the gastrointestinal tract, optionally in a delayed manner. Examples of embedding components that can be used include polymeric substances and waxes. If appropriate, the active ingredient may also be in the form of microcapsules containing one or more of the above-mentioned excipients.

[0091] Formulations for rectal or vaginal administration may be presented as suppositories which may be prepared by mixing one or more compounds of the invention with one or more suitable non-irritating excipients or carriers (including, for example, cocoa butter, polyethylene glycol, suppository wax or salicylates) and which are solid at room temperature but liquid at body temperature and therefore will melt in the rectum or vaginal cavity and release the active compound.

[0092] Formulations suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

[0093] Dosage forms for topical or transdermal administration of the cyclodextrin / ATP inhibitor composition of the present invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.

[0094] Ointments, pastes, creams and gels may contain, in addition to the active compounds of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0095] Powders and sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0096] Transdermal patches have the additional advantage of providing controlled delivery to health. Such dosage forms can be made in a suitable medium by dissolving or dispersing the compound. Absorption enhancers also can be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by providing a rate-controlled membrane or by the compound being dispersed in a polymer matrix or a gel.

[0097] Ophthalmic formulations, eye ointments, powders, solutions, etc. are also contemplated as being within the scope of this invention.

[0098] Pharmaceutical compositions suitable for parenteral administration may comprise sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions prior to use and which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the preparation isotonic with the blood of the intended recipient, or suspending or thickening agents.

[0099] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils, e.g., olive oil, and injectable organic esters, e.g., ethyl oleate. Appropriate fluidity can be maintained, for example, by the use of coating materials, e.g., lecithin, by maintaining the desired particle size in the case of dispersions, and by the use of surfactants.

[0100] In certain embodiments, the pharmaceutical compositions described above can be combined with other pharmacologically active compounds ("second active agents") known in the art according to the methods and compositions provided herein. The second active agent can be a macromolecule (e.g., a protein) or a small molecule (e.g., a synthetic inorganic, organometallic, or organic molecule). In one embodiment, the second active agent independently or synergistically helps treat cancer.

[0101] For example, a chemotherapeutic agent is an anti-cancer agent. The term chemotherapeutic agent includes, but is not limited to, platinum-based drugs such as carboplatin and cisplatin; nitrogen mustard alkylating agents; nitrourea alkylating agents such as carmustine (BCNU) and other alkylating agents; antimetabolites such as methotrexate; purine analog antimetabolites; pyrimidine analog antimetabolites such as floxuridine (5-FU) and gemcitabine; hormonal antitumor agents such as goserelin, leuprolide, and tamoxifen; natural antitumor agents such as taxanes (e.g., docetaxel and paclitaxel), aldesleukin, interleukin-2, etoposide (VP-16), interferon alpha, and retinoic acid (ATRA); antibiotic natural antitumor agents such as bleomycin, actinomycin D, daunorubicin, doxorubicin, and mitomycin; and vinca alkaloid natural antitumor agents such as vinblastine and vincristine.

[0102] In addition, the following drugs can also be used in combination with antineoplastic agents, even if the antineoplastic agents themselves are not considered: actinomycin D; daunorubicin HCl; docetaxel; doxorubicin HCl; epoetin α; etoposide (VP-16); ganciclovir sodium; gentamicin sulfate; interferon α; leuprolide acetate; meperidine HCl; methadone HCl; ranitidine HCl; vinblastine sulfate; and zidovudine (AZT). For example, floxuridine has recently been formulated in combination with epinephrine and bovine collagen to form a particularly effective combination.

[0103] Furthermore, the following list of amino acids, peptides, polypeptides, proteins, polysaccharides, and other macromolecules may also be used: interleukin 1-18, including mutants and analogs; interferons or cytokines, such as interferon α, β and γ; hormones, such as luteinizing hormone releasing hormone (LHRH) and analogs and gonadotropin releasing hormone (GnRH); growth factors, such as transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), nerve growth factor (NGF), growth hormone releasing factor (GHRF), epidermal growth factor (EGF), fibroblast growth factor homologous factor (FGFHF), hepatocyte growth factor (HGF), and insulin growth factor (IGF); tumor necrosis factor-α & β (TNF-α & β); invasion inhibitory factor-2 (IIF-2); bone morphogenetic protein 1-7 (BMP 1-7); somatostatin; thymosin-α-1; γ-globulin; superoxide dismutase (SOD); complement factors; anti-angiogenic factors; antigenic materials; and prodrugs.

[0104] Chemotherapeutic agents useful with the therapeutic compositions and methods described herein include, but are not limited to, alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquinone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, trothamide, triethylenephosphoramide, triethylenephosphoramide sulfide, and trihydroxymethylmelamine; acetogenins (particularly bratacin and bratacinone); camptothecins (including the synthetic analog topotecan); bryostatin; callystatin; CC-1065 (including its adolesine, carzelesine, and biszelesine synthetic analogs); cryptophycins (especially cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, chlorambucil hydrochloride, mefenamic acid, novembichine, phenylephrine, prednimustine, trofosfamide, uracil nitrogen mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine and ranimustine; antibiotics such as enediyne antibiotics (e.g., calicheamicin, particularly calicheamicin γlI and calicheamicin ωl1; enediyne anthracycline antibiotics, including enediyne anthracycline A; bisphosphonates, such as clodronate; esperamicin;and new carcinostatisin chromophores and related chromoprotein enediyne antibiotic chromophores, aclacinomysins, actinomycins, authramycins, azaserine, bleomycin, actinomycin C, carabicin, caminomycin, carzinophilin, chromomycin, actinomycin D, daunorubicin, detorubicin, 6-diaza-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolidino-doxorubicin and deoxy-doxorubicin) anti-inflammatory drugs, anti-fungal drugs, anti-infective drugs, anti-fungal drugs, anti-infective drugs, anti-fungal drugs, anti-infective drugs, anti-fungal drugs, anti-infective drugs, anti-fungal drugs, anti-infective drugs, anti-fungal drugs, anti-infective drugs, anti-fungal drugs, anti-infective drugs, anti-fungal drugs, anti-infective drugs, anti-fungal drugs, anti-fungal drugs, anti-fungal drugs, anti-fungal drugs, anti-fungal drugs, anti-fungal drugs, anti-fungal drugs, - metabolites such as methotrexate and 5-fluorouridine (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, deoxyfluridine doxifluridine, enocitabine, floxuridine; androgen such as calusterone, dromostanolonepropionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as folinic acid;aceglatone; aldophosphamideglycoside; aminolevulinic acid; eniluracil; amsacrine; bwstrabucil, bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate acetate; epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharide complex); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid acid; triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A, and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, such as paclitaxel, docetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes, such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine;Vinorelbine; mitoxantrone hydrochloride; teniposide; edatrexate; daunorubicin; aminopterin; xeloda; ibandronate sodium; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as tretinoin; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above drugs. ;

[0105] In another embodiment, the compositions of the invention may contain other biologically active substances, including therapeutic drugs or prodrugs, for example, other chemotherapeutic agents, scavenger compounds, antibiotics, anti-viral agents, anti-fungal agents, anti-inflammatory drugs, vasoconstrictors and anticoagulants, antigens for cancer vaccine applications or corresponding prodrugs.

[0106] Exemplary scavenger compounds include, but are not limited to, sulfhydryl-containing compounds such as glutathione, thiourea, and cysteine; alcohols such as mannitol, substituted phenols; quinones, substituted phenols, aromatic amines, and nitro compounds.

[0107] Various forms of chemotherapeutic agents and / or other biologically active agents may be employed. These include, but are not limited to, for example, uncharged molecules, molecular complexes, salts, ethers, esters, amides, etc., which are biologically active.

[0108] E. Methods for Preparing Cyclodextrin / ATP Inhibitor Compositions

[0109] The method for preparing cyclodextrin / ATP inhibitor compositions and their preparations comprises the step of mixing the compound of the present invention with a carrier and optionally one or more auxiliary components. In general, the preparation is prepared by uniformly and intimately mixing the selective inhibitor of ATP production described herein with cyclodextrin. In general, such a complex can be obtained by stirring and mixing cyclodextrin (e.g., a solution containing cyclodextrin) while dripping a therapeutic agent (e.g., a solution containing a selective inhibitor of ATP production), or vice versa. 。Many mixing methods that facilitate the combination of inhibitors and cyclodextrins are known in the art, such as, but not limited to, ultrasonic treatment, vortexing, stirring, heating, coprecipitation, neutralization, pulping, kneading, grinding, etc. Depending on the physical properties of the therapeutic agent, it is possible to use a substance that is soluble in a solvent or a solid substance as the therapeutic agent. There are no particular restrictions on the solvent, and one can use, for example, the same substance as the cyclodextrin external phase. The amount of the therapeutic agent mixed with the cyclodextrin can be equimolar or in different proportions, depending on the level of combination required. In some embodiments, the absolute amount of the selective inhibitor of ATP production can be in the range of 0.001-10 mol equivalents, 0.01-1 mol equivalents, or any range included relative to the amount of cyclodextrin. Similarly, there is no particular restriction on the heating temperature. For example, 5°C or higher, room temperature or higher (for example, 20°C or higher is also preferred) are all acceptable.

[0110] There are well-known methods for removing any unwanted or unbound complexes or compositions, such as therapeutic agents that are not encapsulated by cyclodextrins or therapeutic agent cyclodextrin complexes that are not encapsulated by liposomes. Representative examples include, but are not limited to, dialysis, centrifugation, and gel filtration. Dialysis can be performed, for example, using a dialysis membrane. As a dialysis membrane, one can cite a membrane with a molecular weight cutoff such as a cellulose tube or Spectra / Por. As for centrifugation, the centrifugal acceleration can preferably be performed at 100,000 g or higher, and more preferably at 300,000 g or higher. Gel filtration can, for example, be performed by fractionating based on molecular weight using a column such as Sephadex or Sepharose.

[0111] In some cases, to prolong the drug effect, it is desirable to change (e.g., slow down) the absorption of the drug from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of a crystalline or amorphous material with poor water solubility. The absorption rate of the drug depends on the rate at which it dissolves, which in turn can depend on the crystal size and crystalline form. Alternatively, the delayed absorption of a parenteral-administered drug form can be achieved by dissolving or suspending the drug in an oily vehicle. In some embodiments, the cyclodextrin-encapsulated selective ATP inhibitor compositions described herein can be loaded into liposomes.

[0112] Injectable depot forms are prepared by forming a microencapsulation matrix of the present compound in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the properties of the specific polymer used, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

[0113] F. Treatment

[0114] The present invention also provides new methods for preventing, delaying, alleviating, and / or treating cancer, including cancerous tumors. In one embodiment, a method of treatment includes administering an effective amount of a cyclodextrin / selective ATP production inhibitor composition to a subject (e.g., a subject in need thereof). Subjects in need thereof may include, for example, subjects diagnosed with tumors, including precancerous tumors, cancers, or subjects who have been treated, including subjects who have not responded to previous treatments.

[0115] The term "effective amount" as in "therapeutically effective amount" of a therapeutic agent refers to the amount of a drug necessary to elicit a desired biological response. As will be appreciated by one of ordinary skill in the art, the effective amount of a drug may vary depending on factors such as the desired biological endpoint, the drug to be delivered, the composition of the pharmaceutical composition, the target tissue or cell, etc. More specifically, the term "effective amount" refers to an amount sufficient to produce a desired effect, e.g., to reduce or alleviate the severity, duration, progression, or occurrence of a disease, disorder, or condition, or one or more symptoms thereof; to prevent the progression of a disease, disorder, or condition, to cause regression of a disease, disorder, or condition; to prevent the recurrence, development, occurrence, or progression of symptoms associated with a disease, disorder, or condition, or to enhance or improve the prophylactic or therapeutic effect of another therapy.

[0116] The method of the present invention can be used to treat any cancerous or precancerous tumor. In certain embodiments, the cancerous tumor has a high glycolytic phenotype. For example, a high degree of glycolytic tumors can be located in a tissue selected from the following: brain, colon, urogenital, lung, kidney, prostate, pancreas, liver, esophagus, stomach, hematopoietic tissue, breast, thymus, testis, ovary, skin, bone marrow and / or uterine tissue. In some embodiments, the method and composition of the present invention can be used to treat any cancer. Cancers that can be treated by the method and composition of the present invention include, but are not limited to, cancer cells from bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal, gums, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus. In addition, the cancer may specifically be of the following histological types, although it is not limited to these: tumor, malignant tumor; carcinoma; undifferentiated carcinoma; giant cell carcinoma and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; malignant gastrinoma; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyps; adenocarcinoma, familial polyposis coli; solid tumor; malignant carcinoid tumor; bronchio-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe cell carcinoma carcinoma; oncocytic carcinoma; oxyphilicadenocarcinoma; basophilic carcinoma; clear cell carcinoma; granulocytic carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenocortical carcinoma; endometrioid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous gland carcinoma; cerocerebrovascular carcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; serous papillary cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating ductal carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; Paget's disease disease), breast cancer, acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w / squamous metaplasia; malignant thymoma; malignant ovarian stromal tumor; malignant theca cell tumor; malignant granulocytoma; and malignant blastoma; sertoli cell; malignant leydig cell tumor (leydig cell tumor, malignant); malignant lipid cell tumor; malignant paraganglioma; malignant extramammary paraganglioma; pheochromocytoma; glomangiosarcoma; malignant melanoma;amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant nevus; epithelioid cell melanoma; malignant blue nevus (malignant); sarcoma; fibrosarcoma; malignant fibrous histiocytoma; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; malignant mixed tumor, mullerian mixed tumor; Wilms' tumor; hepatoblastoma; carcinosarcoma; malignant stromal tumor; malignant Brenner tumor (malignant); malignant phyllodes tumor; synovial sarcoma; malignant mesothelioma, dysgerminoma; embryonal carcinoma; malignant teratoma; malignant ovarian glandular tumor; choriocarcinoma; malignant mesonephroma (mesonephroma, malignant; angiosarcoma; malignant hemangioendothelioma; Kaposi's sarcoma; malignant hemangiopericytoma; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; malignant chondroblastoma; mesenchymal chondrosarcoma; giant cell tumor of bone; Ewing's sarcoma; malignant odontogenic tumor; ameloblastic odontosarcoma; malignant ameloblastoma; ameloblastic fibrosarcoma; malignant pinealoma; chordoma; malignant glioma; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroblastoma; oligodendroblastoma; primitive neuroectodermal neuroectodermal); cerebellar sarcoma; ganglioblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; malignant meningioma; neurofibrosarcoma; malignant schwannoma; malignant granulocytic tumor; malignant lymphoma; Hodgkin's disease; Hodgkin's lymphoma; paragranuloma; small lymphocytic malignant lymphoma; diffuse large cell malignant lymphoma; malignant follicular lymphoma; mycosis fungoides; other non-Hodgkin's King's lymphoma; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia.

[0117] The compositions described herein can be delivered by any suitable route of administration, including orally, nasally, transmucosally, intraocularly, rectally, intravaginally, parenterally, including intramuscular, subcutaneous, intramedullary injection, as well as intrathecally, directly intraventricularly, intravenously, intraarticularly, intrasternal, intrasynovially, intrahepatically, intralesionally, intracranially, intraperitoneally, intranasally, or intraocularly, intracisternal, topically, as a powder, ointment or drops (including eye drops), including buccal and sublingual, transdermally, by inhalation spray, or other delivery methods known in the art.

[0118] As used herein, the terms "systemic administration," "systemic administration," "peripheral administration," and "peripheral administration" mean administration of the selective ATP production inhibitor / cyclodextrin complex so that it enters the patient's system and thereby undergoes metabolism and other similar processes.

[0119] As used herein, the terms "parenteral administration" and "parenteral administration" refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intraocular, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

[0120] In certain embodiments, the pharmaceutical composition is delivered systemically (e.g., via oral or parenteral administration). In certain other embodiments, the pharmaceutical composition is delivered locally by direct injection into a tumor or by direct injection into the blood supply (e.g., arterial or venous blood supply) of a tumor. In some embodiments, the pharmaceutical composition is delivered by systemic and local administration. For example, a subject with a tumor can be treated by direct injection of a composition containing a composition described herein into a tumor or the blood supply of a tumor in combination with oral administration of a pharmaceutical composition of the present invention. If local and systemic administration is employed, local administration can occur before systemic administration, simultaneously with systemic administration, and / or after systemic administration.

[0121] In certain embodiments, the methods of treatment of the present invention, including treatment of cancerous or pre-cancerous tumors, include administering to the subject a composition described herein in combination with a second drug and / or therapy. By "in combination with..." is meant administering the selective ATP production inhibitor / cyclodextrin complex with one or more therapeutic agents either simultaneously, sequentially, or in combination thereof. Thus, a subject administered a combination of a selective ATP production inhibitor / cyclodextrin complex and / or therapeutic agent may receive the selective ATP production inhibitor / cyclodextrin complex as described herein, and one or more therapeutic agents at the same time (i.e., simultaneously) or at different times (i.e., sequentially, in either order on the same day or on different days), as long as the combined effect of the two drugs is achieved in the subject. When administered sequentially, the drugs may be administered within 1, 5, 10, 30, 60, 120, 180, 240 minutes or longer of each other. In other embodiments, the sequentially administered drugs may be administered within 1, 5, 10, 15, 20 or more days of each other.

[0122] When administered in combination, the effective concentration of each drug to elicit a specific biological response may be less than the effective concentration of each drug when administered alone, thereby allowing a reduction in the dose of one or more drugs relative to the dose required if the drugs were administered as a single drug. The effects of multiple drugs may be, but need not necessarily be, additive or synergistic. Drugs may be administered multiple times. In such combination therapy, subsequent drugs may be administered sequentially, simultaneously, or separately while the therapeutic effect of the first administered drug has not yet worn off.

[0123] In certain embodiments, such methods include administering a pharmaceutical composition comprising a composition described herein in combination with one or more chemotherapeutic agents and / or antioxidant compounds, including chemotherapeutic agents described herein, and other drugs known in the art. Combination therapy includes sequentially, simultaneously and separately, or co-administering the composition in such a manner that the therapeutic effect of the first selective ATP inhibitor administered has not completely disappeared when the subsequent compound is administered. In one embodiment, the second drug is a chemotherapeutic agent. In another embodiment, the second drug is an antioxidant compound. In another embodiment, the second drug is radiotherapy. In a further embodiment, radiotherapy may also be administered in addition to the composition. In certain embodiments, the second drug may be co-formulated with a separate pharmaceutical composition.

[0124] In some embodiments, the pharmaceutical compositions of the present invention will incorporate an amount of one or more substances to be delivered, an amount sufficient to deliver to a patient a therapeutically effective amount of a combined therapeutic agent or other material as part of a preventive or therapeutic treatment. The desired concentration of the active compound in the microparticles will depend on the absorption, inactivation and excretion rates of the drug and the delivery rate of the compound. It is noted that dosage values ​​may also vary with the severity of the condition to be alleviated. It is further understood that for any particular subject, the specific dosage regimen should be adjusted over time based on individual needs and the professional judgment of the person administering or monitoring the administration of the composition. Typically, the dosage will be determined using techniques known to those skilled in the art.

[0125] Dosage can be based on the amount of the composition or its active compound (e.g., a selective inhibitor of ATP production) per kg of patient body weight. For example, a range of amounts of the composition or compound encapsulated therein is designed to include about 0.001, 0.01, 0.1, 0.5, 1, 10, 15, 20, 25, 50, 75, 100, 150, 200 or 250 mg or more of such composition per kg of patient body weight. Other amounts will be known and easily determined by those skilled in the art.

[0126] In certain embodiments, the dosage of the composition or its active compound (e.g., a selective inhibitor of ATP production) will generally be in the range of about 0.001 mg to about 250 mg per kg body weight, particularly in the range of about 50 mg to about 200 mg per kg body weight, and more particularly in the range of about 100 mg to about 200 mg per kg body weight. In one embodiment, the dosage is in the range of about 150 mg to about 250 mg per kg body weight. In another embodiment, the dosage is about 200 mg per kg body weight.

[0127] In some embodiments, the molar concentration of the composition or its active compound (e.g., a selective inhibitor of ATP production) in the pharmaceutical composition will be less than or equal to about 2.5 M, 2.4 M, 2.3 M, 2.2 M, 2.1 M, 2 M, 1.9 M, 1.8 M, 1.7 M, 1.6 M, 1.5 M, 1.4 M, 1.3 M, 1.2 M, 1.1 M, 1 M, 0.9 M, 0.8 M, 0.7 M, 0.6 M, 0.5 M, 0.4 M, 0.3 M, or 0.2 M. In some embodiments, the concentration of the composition or its active compound (e.g., a selective inhibitor of ATP production) will be less than or equal to about 0.10 mg / ml, 0.09 mg / ml, 0.08 mg / ml, 0.07 mg / ml, 0.06 mg / ml, 0.05 mg / ml, 0.04 mg / ml, 0.03 mg / ml, or 0.02 mg / ml.

[0128] Alternatively, dosage can be determined by reference to the plasma concentration of the composition or its active compound (e.g., a selective inhibitor of ATP production). For example, the maximum plasma concentration (C max ) and the area under the plasma concentration-time curve from time 0-infinity (AUC (0-4)). The dosage of the present invention includes the production of max and AUC (0-4) and other doses above those values ​​that result in larger or smaller values ​​for those parameters.

[0129] Actual dosage levels of the active ingredients of the compositions of the invention may be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0130] The selected dosage level will depend upon a variety of factors including the activity of the particular therapeutic agent, or its ester, salt or amide, in the formulation employed, the route of administration, the time of administration, the rate of excretion or metabolism of the particular therapeutic agent being employed, the duration of the treatment, other drugs, compounds and / or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient to be treated, and other factors well known in the medical art.

[0131] A clinician or veterinarian with ordinary skills in the art can easily determine and prescribe the effective amount of the desired pharmaceutical composition. For example, a clinician or veterinarian can prescribe and / or administer a compound of the present invention for use in a pharmaceutical composition at a dosage lower than the desired level to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0132] In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

[0133] If desired, the effective daily dose of the active compound may be administered as two, 3, 4, 5, 6 or more divided sub-doses administered at appropriate intervals throughout the day, optionally in a single dose.

[0134] The exact time and amount of administration of any particular compound that will produce the most effective treatment in a given patient will depend on the activity, pharmacokinetics and bioavailability of the particular compound, the patient's physiological conditions (including age, sex, disease type and stage, general physical condition, responsiveness to the dose and type of a given drug), route of administration, etc. The dosing guidelines set forth herein can be used to optimize treatment, for example, to determine the optimal time and / or amount of administration, which will not require more than routine experimentation consisting of monitoring the subject and adjusting the dose and / or time.

[0135] While the subject is receiving treatment, the health of the patient can be monitored by measuring one or more relevant indicators at a predetermined time during a 24-hour period. All treatment aspects, including the supplementation, amount, and frequency of administration and preparation, can be optimized based on the results of such monitoring. The patient can be reassessed regularly to determine the degree of improvement by measuring the same parameters, and the first such reassessment usually occurs at the end of the 4th week from the start of treatment, and subsequent reassessments occur every 4-8 weeks during the treatment period, and then every 3 months thereafter. Treatment can continue for several months or even years, and at least one month is a typical course of treatment for people. Adjustment, for example, of the amount of the drug given and the number of administrations can be carried out based on these reassessments.

[0136] Treatment may be initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage may be increased by small increments until the optimum therapeutic effect is achieved.

[0137] As described above, the composition or its active compound (e.g., a selective inhibitor of ATP production) can be administered in combination with radiotherapy. The optimal dose of radiotherapy can be administered to the subject as a daily dose. The optimal daily dose of radiotherapy can be, for example, from about 0.25-0.5 Gy, about 0.5-1.0 Gy, about 1.0-1.5 Gy, about 1.5-2.0 Gy, about 2.0-2.5 Gy, and about 2.5-3.0 Gy. An exemplary daily dose can be, for example, from about 2.0-3.0 Gy. For example, if the tumor is resistant to lower doses of radiation, a higher dose of radiation can be given. High doses of radiation can reach, for example, 4 Gy. In addition, the total radiation dose given during treatment can be, for example, in the range of from about 50-200 Gy. In an exemplary embodiment, the total radiation dose given during treatment ranges from, for example, about 50-80 Gy. In certain embodiments, doses of radiation may be administered at time intervals of, for example, 1, 2, 3, 4, or 5 minutes, where the amount of time depends on the administration rate of the radiation source.

[0138] In certain embodiments, the optimal daily dose of radiation can be given, for example, 4 or 5 days per week, for about 4-8 weeks. In alternative embodiments, the optimal daily dose of radiation can be given 7 days a week, daily, for about 4-8 weeks. In certain embodiments, the daily dose of radiation can be given in a single dose. Alternatively, the daily dose of radiation can be given as multiple doses. In further embodiments, the optimal dose of radiation can be a higher radiation dose than the patient's tolerable dose based on a daily basis. Therefore, high doses of radiation can be given to patients, but with less frequent dosage regimens.

[0139] Types of radiation that can be used to treat cancer are well known in the art and include electron beams, high energy photons from linear accelerators or radioactive sources such as cobalt or cesium, protons, and neutrons. An exemplary ionizing radiation is x-ray radiation.

[0140] Methods for administering radiation are well known in the art. Exemplary methods include, but are not limited to, external beam radiation, internal beam radiation, and radiopharmaceuticals. In external beam radiation, a linear accelerator is used to deliver high-energy x-rays to areas of the body affected by cancer. Since the radiation source originates outside the body, external beam radiation can be used to treat large areas of the body with uniform dose radiation. Internal radiation therapy, also known as brachytherapy, involves delivering high doses of radiation to specific parts of the body. Two main types of internal radiation therapy include intra-tissue radiation therapy, in which the radiation source is placed in the affected tissue, and intracavitary radiation therapy, in which the radiation source is placed in an internal body cavity at a short distance from the affected area. Radioactive materials can also be delivered to tumor cells by being connected to tumor-specific antibodies. Radioactive materials used for internal radiation therapy are typically contained in small capsules, pellets, wires, tubes, or implants. In contrast, radiopharmaceuticals are unsealed radiation sources that can be administered orally, intravenously, or directly into a body cavity.

[0141] Radiation therapy may also include stereotactic surgery or stereotactic radiotherapy, in which precise amounts of radiation can be delivered to small tumor areas using a linear accelerator or gamma knife and three-dimensional stereotactic conformal radiation therapy (3DCRT), a computer-assisted therapy that maps the morphology of the tumor location prior to radiation treatment.

[0142] The toxicity and therapeutic efficacy of the present compounds can be determined by measuring the LD in cell culture or experimental animals, for example 50 and ED 50 The LD can be measured by standard pharmacological procedures. Compositions that exhibit large therapeutic indices are preferred. In some embodiments, LD 50 (lethal dose) and for the cyclodextrin-encapsulated selective ATP inhibitor compositions described herein can be, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or more reduction relative to the selective ATP inhibitor without any cyclodextrin encapsulation. Similarly, ED can be measured 50 (i.e., the concentration that achieves half-maximal inhibition of symptoms) and for the cyclodextrin-encapsulated selective ATP inhibitor compositions described herein can be, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or more increase relative to the selective ATP inhibitor without any cyclodextrin encapsulation. Likewise, the IC 50(i.e., a concentration that achieves half-maximal cytotoxic or cytostatic effects on cancer cells) and for the cyclodextrin-encapsulated selective ATP inhibitor compositions described herein can be, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or more increase relative to the selective ATP inhibitor without any cyclodextrin encapsulation. Although compounds that exhibit toxic side effects can be used, it should be noted that it is important to design a delivery system that targets the compound to the desired site to reduce side effects.

[0143] In some embodiments, the methods of the present disclosure produce at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or even 100% inhibition of cancer cell growth in an assay.

[0144] In any of the above methods, administration of the selective ATP production inhibitor / cyclodextrin complex can result in at least about a 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or even 100% reduction in the solid malignancy in the subject compared to the solid malignancy prior to administration of the selective ATP production inhibitor / cyclodextrin complex.

[0145] In some embodiments, a therapeutically effective amount of a selective ATP production inhibitor / cyclodextrin complex is administered prophylactically to prevent a subject from developing a solid malignancy.

[0146] In some embodiments, the subject is a human. In other embodiments, the subject is not a human, such as a mammal.

[0147] The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of any supplement, or alternatively any component thereof, is preferably within the range of ED 50 The dosage may vary within this range depending on the dosage form employed and the route of administration utilized. For the drugs of the invention, the therapeutically effective amount may be estimated initially from cell culture assays. The dosage may be formulated in animal models to achieve an IC value including that determined in cell culture. 50 The circulating plasma concentration range of the drug can be determined by the method of the invention. Such information can be used to more accurately determine useful doses in humans. The levels in plasma can be measured, for example, by high performance liquid chromatography.

[0148] G. Medicine Box

[0149] The selective ATP production inhibitor / cyclodextrin complexes and compositions described herein can be assembled into a kit or drug system for treating or preventing a disease, such as cancer. In some embodiments, the 3-BrPA-cyclodextrin complex and composition can be used to prevent or treat solid malignancies caused by cancer. In general, the kit of the present disclosure contains some or all of the components, reagents, supplements, etc. to implement the method according to the disclosed subject matter. The kit generally contains an effective amount of the complex to prevent, delay, reduce, or treat a harmful disease (e.g., solid malignancies). In one embodiment, the kit includes at least one container (e.g., cardboard, glass bottle, vial, tube, or ampoule) containing the selective ATP production inhibitor / cyclodextrin complex described herein and / or its composition. Typically, the complex and / or composition will be supplied in one or more containers, each container containing an effective amount of the complex to cause solid malignancies to regress, slow down, or be inhibited.

[0150] Thus, in some embodiments, the presently disclosed subject matter provides a kit comprising at least one selective ATP production inhibitor encapsulated in at least one cyclodextrin carrier. In other embodiments, the kit further comprises a set of instructions for using at least one selective ATP production inhibitor encapsulated in at least one cyclodextrin carrier.

[0151] It may be desirable to store the selective ATP production inhibitor and the cyclodextrin separately and then combine them prior to use. Thus, in still other embodiments, the kit comprises at least one selective ATP production inhibitor in one container and at least one cyclodextrin carrier in another container.

[0152] example

[0153] The following examples have been included to provide guidance to those of ordinary skill in the art for practicing representative embodiments of the disclosed subject matter. In light of the present disclosure and the general level of skill in the art, the skilled artisan will appreciate that the following examples are meant to be exemplary only and that many variations, modifications, and alterations may be employed without departing from the scope of the presently disclosed subject matter. The following examples are provided by way of illustration and not limitation.

[0154] Example 1: Materials and methods for Examples 2-3

[0155] A. General Method for Synthesis of Modified β-Cyclodextrins

[0156] Succinyl-β-cyclodextrin was purchased from Sigma Chemical (St. Louis, MO, USA; catalog number 85990). Unmodified β-cyclodextrin and α-cyclodextrin were purchased (Sigma-Aldrich, St. Louis, MO).

[0157] However, succinylated cyclodextrins can also be synthesized. For example, the 6' primary hydroxyl group of β-cyclodextrin (Sigma-Aldrich, St. Louis, MO) was mono-tosylated with 0.9 molar equivalents of tosyl chloride in pyridine to provide the corresponding tosylate, which was converted to the iodo-derivative by treatment with sodium iodide in acetone. The iodo-derivative was converted to the desired 6'aminated cyclodextrin by heating with an appropriate amine at 80 °C for 8-12 h (Tang and Ng (2008) Nat. Protocol. 3:691-697). 6'-monosuccinyl-β-cyclodextrin was synthesized by treating the parent β-cyclodextrin with 0.9 equivalents of succinic anhydride in DMF (Cucinotta et al. (2005) J. Pharmaceut. Biomed. Anal. 37: 1009-1014). The product was precipitated in acetone and purified by HPLC before use.

[0158] The pH range for optimal stability is pH 4-9.

[0159] B. General Procedure for Preparing Encapsulated Complexes

[0160] 3-BrPA encapsulated in succinyl-β-cyclodextrin was prepared in a 1:1 ratio. 3-BrPA (150 mg, 1 mmol) was added in small portions (10 mg each) to a stirred solution of succinyl-β-cyclodextrin (1,500 mg in distilled water). After the addition was complete, the solution was sonicated at room temperature for 1 hour. The sonicated solution was then allowed to shake overnight at 25°C in a thermomixer, flash frozen in a dry ice-acetone bath, and lyophilized.

[0161] Similarly, 3-BrPA encapsulated in succinyl-β-cyclodextrin was prepared in a 2:1 ratio. 3-BrPA (166 mg, 1 mmol) was added in small portions (10 mg each time) to a stirred solution of succinyl-β-cyclodextrin (918 mg in 20 ml of distilled water). After the addition was complete, the solution was sonicated at room temperature for 1 hour. The sonicated solution was then allowed to shake overnight at 25°C in a thermomixer, quickly frozen in a dry ice-acetone bath and lyophilized.

[0162] Additionally, 3-BrPA encapsulated in α-cyclodextrin (see structure below) was prepared in a 1:1 ratio. 3-BrPA (166 mg, 1 mmol) was added in small portions (10 mg each time) to a stirred solution of α-cyclodextrin (972 mg, 1 mmol in 10 ml distilled water). After the addition was complete, the solution was sonicated for 1 hour at room temperature. The sonicated solution was then allowed to shake overnight at 25°C in a thermomixer, flash frozen in a dry ice-acetone bath and lyophilized. Non-GRAS and GRAS versions were used with similar results.

[0163] α-Cyclodextrin Structure

[0164]

[0165] It has surprisingly been determined that modified cyclodextrins having one or more hydroxyl groups on one or more of their α-D-glucopyranoside units replaced with ionizable groups generating a negative charge (anion) stabilize 3-halopyruvic acid better than those cyclodextrins having ionizable groups generating a positive charge (cation) or unmodified cyclodextrins, such as unmodified α- or β-cyclodextrin. It has also surprisingly been determined that β-cyclodextrin encapsulates 3-BrPA in a form that protects and stabilizes 3-BrPA, particularly significantly better than α-cyclodextrin in terms of in vivo efficacy and also in terms of in vitro efficacy.

[0166] In addition, in vitro cell cultures and in vivo mouse treatments were prepared and performed as described above and below for succinyl-β-cyclodextrin encapsulated 3-BrPA, using a generally recognized as safe (GRAS) version of β-cyclodextrin (e.g., hydroxypropyl-β-cyclodextrin having a substitution level of 3-5 as shown in the chemical form below) encapsulated 3-BrPA, and the results were similar to those described for succinyl-β-cyclodextrin encapsulated 3-BrPA.

[0167] GRAS Hydroxypropyl-β-cyclodextrin Structure

[0168]

[0169] C. In vitro cell culture

[0170] 3-BrPA and β-cyclodextrin (vehicle) were purchased from Sigma Chemical (St. Louis, MO, USA). For viability assays, MiaPaCa-2 and Suit-2 cells were plated at 5 × 10 3Cells were seeded in triplicate at a density of 100 μM per well in 96-well plates. After 12 h, cells were treated with increasing concentrations of 3-BrPA, CD-3BrPA (0-150 μM), and vehicle. Intracellular ATP levels were determined using the Cell Titer-Glo Luminescence Cell Viability Assay Kit (Promega, Durham, NC, USA) according to the manufacturer's protocol. Measurements were performed 24 and 72 h after treatment.

[0171] D. In vivo treatment of mice

[0172] A total of 15 animals were randomized to receive daily injections of 5 mg / kg β-CD-3BrPA (at a 1:1 ratio) (N=10) or vehicle control (N=5). Baseline bioluminescence imaging confirmed tumor growth in all animals (at Figure 4 and 5 5 representative animals are shown in ). All animals were subjected to follow-up imaging 2 weeks after intraperitoneal injection. Animals treated with vehicle showed a strong increase in bioluminescent signal, indicating tumor progression.

[0173] Male athymic nude mice (20-25 g, 4 weeks old, Crl:Nu-Nu, Charles River Laboratories, Wilmington, MA, USA) were used according to institutional guidelines of approved protocols. Mice were maintained in a laminar flow chamber under constant temperature and humidity with free access to food and water. The MiaPaCa-2 cell line stably transfected with a luciferase-aminoglycoside phosphotransferase fusion gene under the control of the elongation factor 1α promoter was used. Mice were anesthetized by isoflurane inhalation anesthesia prior to surgery and treatment. A small left ventral incision was made and the pancreas was removed from the abdomen. The pancreas was injected with 1-2 x 10 6 MiaPaCa-2 cells enter the pancreatic tail, generating orthotopic pancreatic tumors. Successful subcapsular intrapancreatic injection of tumor cells was identified by the appearance of fluid blebs without intraperitoneal leakage.

[0174] For bioluminescent imaging (BLI), anesthetized mice bearing orthotopic tumors were injected intraperitoneally with 150 mg / kg of D-luciferin (Gold Biotechnilogy, St Louis, MO, USA) and imaged 5 minutes later using IVIS 100 (Xenogen Corp, Alameda, CA, USA) optical imaging. Pseudo-color images representing the spatial distribution of detected photons were superimposed on grayscale photographic images. After 10 seconds of exposure using Living Image software (XenogenCorp.), ROIs were used to quantify signal intensity (p / s / cm2 / Sr). Imaging was performed 7, 14, 21, 28, and 35 days after tumor implantation.

[0175] After tumor growth was confirmed in each animal using BLI one week after tumor implantation, all animals were randomized into 3 groups to receive either 3-BrPA, CD-3BrPA, or vehicle via daily intraperitoneal injections (injection volume, 500 μl / mouse / day; dose, 5 mg / kg). The injection solution was prepared by dissolving the chemical in phosphate-buffered saline, adjusted to pH 7.4. The animals were observed every hour during the initial injection period and every 4-6 hours after each subsequent injection. Any changes in the overall clinical condition were recorded for all treatment groups.

[0176] Animals were sacrificed using cervical dislocation within 24 hours after the last BLI imaging. The entire abdomen was opened and tumors were obtained using en bloc extraction of the spleen and pancreas. Tumor samples were fixed with 4% paraformaldehyde for 72 hours, embedded in paraffin and sectioned. Histological sections were stained with hematoxylin and eosin (H&E) and interpreted by a consulting pathologist.

[0177] Example 2: Effects of cyclodextrin-encapsulated 3-BrPA on human pancreatic cancer cell lines in vitro

[0178] Two cell lines of human pancreatic cancer, MiapaCa-2 and Suit-2, were tested for their response to 3-BrPA and CD-3-BrPA. MiaPaCa-2 is derived from a locally invasive human adenocarcinoma and forms typical solid nodules within the pancreas. It is known to show significant resistance to several standard of care anticancer agents, including gemcitabine. Suit-2 is derived from a highly aggressive pancreatic tumor that has been isolated from a metastatic liver mass. It has highly aggressive phenotypic properties, such as invasiveness and migration. Cellular response or cell viability was determined using a standard ATP viability assay. Each experiment was repeated at least twice, using three replicate biological samples.

[0179] Figure 2A-2B shows the effects of 3-BrPA (conventional 3-BrPA in phosphate-buffered saline without any cyclodextrin encapsulation or complex formation) or β-CD-3-BrPA (succinyl-β-cyclodextrin encapsulated 3-BrPA in phosphate-buffered saline) on MiaPaCa-2 cells ( Figure 2 A) and Suit-2 cells ( Figure 2 B) Effects after 24 hours of treatment. The data show a dose-dependent decrease in viability of cells treated with β-CD-3-BrPA compared to 3-BrPA treated cells. In addition, multidrug resistant MiaPaCa2 cells were found to be more sensitive to 3-BrPA / CD-3-BrPA than Suit2 cells. The vehicle (β-cyclodextrin in phosphate-buffered saline without any 3-BrPA) itself did not cause any toxicity.

[0180] Figure 3 The effects of 3-BrPA (conventional 3-BrPA in phosphate-buffered saline without any cyclodextrin encapsulation or complex formation) or β-CD-3-BrPA (succinyl-β-cyclodextrin encapsulated BrPA in phosphate-buffered saline) on MiaPaCa2 cells after 72 hours of treatment are shown. MiaPaCa-2 cells showed a significant loss of viability even at ~50 uM concentration of CD-3-BrPA for 72 hours, while treatment with the same concentration for 24 hours ( Figure 2 A), with no apparent loss of viability. Thus, with a longer duration of treatment (48 hours), a relatively low concentration (50 uM) of CD-3-BrPA was sufficient to initiate cell death (~50% death) ( Figure 3 ).

[0181] Example 3: Materials and in vivo effects of cyclodextrin-encapsulated 3-BrPA in a mouse model of human pancreatic cancer

[0182] An athymic mouse model of human pancreatic cancer was used in the in vivo study. A human pancreatic cancer cell line, MiaPaca-2, stably expressing the luciferase gene, was orthotopically implanted into the pancreas. Tumor growth and response were monitored by bioluminescent imaging.

[0183] Table 1 describes the clinical signs or symptoms observed in tumor-bearing animals treated with high-dose 3-BrPA or CD-3-BrPA. These symptoms were recorded in an unbiased and blind-study manner. These symptoms were observed at doses >5 mg / kg body weight and at concentrations ~3.5 mM (higher than the recommended therapeutic dose). Unwanted clinical signs or symptoms were found in mice treated with 3-BrPA, and these signs or symptoms were significantly less than those in mice treated with CD-3-BrPA, indicating that the cyclodextrin carrier protected the subjects from the side effects of the 3-BrPA molecule.

[0184] Table 1

[0185]

[0186] Animals treated with succinyl-β-cyclodextrin-3-BrPA showed complete or nearly-complete tumor responses as measured by bioluminescent imaging ( Figure 4 and 5 ). The animals were then sacrificed for autopsy confirmation of the bioluminescence results ( Figure 4 ). The results indicate that CD-3BrPA retains its anticancer activity even after forming a complex with CD.

[0187] Histopathological analysis of orthotopic MiaPaCa-2 tumors was performed. Figure 6 Hematoxylin and eosin (H&E) stained tumors showed no changes in the control group, while tumors harvested from treated animals showed extensive central necrosis as well as areas of free tumor tissue.

[0188] Thus, it has been determined that cyclodextrin complex formation does not affect the anticancer properties of 3-BrPA, as demonstrated from in vitro and in vivo data. Likewise, the activity of 3-BrPA may be maintained or protected by CD until it is delivered or distributed to the target organ or tumor. Furthermore, administration of CD-3-BrPA to animals results in less toxicity or associated-clinical signs than 3-BrPA alone.

[0189] Example 4: Materials and methods for Examples 5-6

[0190] The experiments described in Examples 2-3 were extended using the following materials and methods to advance the results obtained therefrom. For example, pancreatic ductal adenocarcinoma (PDAC) ranks as the fourth most common cause of cancer-related death in the world (Siegel et al. (2014) CA Canc. J. Clin. 64:9-29). As most patients are diagnosed at an advanced stage, treatment options remain limited and the prognosis is dismal, with a 5-year survival rate of less than 5% (Hidalgo (2010) New Engl. J. Med.362:1605-1617). The past two decades have brought significant advances in the understanding of tumorigenesis and disease progression in pancreatic cancer, which can now be viewed as a distinct and multifactorial neoplastic process (Hidalgo (2010) New Engl. J. Med. 362:1605-1617; Hanahan and Weinberg (2011) Cell 144: 646-674). Pancreatic tumor tissue is composed of several unique cellular and non-cellular elements including a collagen-rich, poorly vascularized, highly hypoxic, non-neoplastic stroma (Chu et al. (2007) J. Cell. Biochem. 101:887-907; Mahadevan and Von Hoff (207) Mol. Canc. Therapeutic. 6:1186-1197). These characteristics are associated with prominent chemoresistance to the most commonly used systemically applied anticancer agents, such as gemcitabine (Muerkoster et al. (2004) Cancer Res. 64:1331-1337; Yokoi and Fidler (2004) Clin. Canc. Res. 10:2299-2306). Of note, altered energy metabolism has recently been added to the organizing principles of the tumor microenvironment and can now be considered a “hallmarker” of pancreatic cancer (Hanahan and Weinberg (2011) Cell 144:646-674; Guillaumond et al. (2014) Arch. Biochem. Biophys 545:69-73. Oxygen-independence of glycolysis as the main axis of energy supply for cancer cells has long been referred to as the "Warburg effect"; however, this phenomenon has not been clinically exploited for therapeutic purposes (Warburg et al. (1927) J. Gen. Physiol. 8:519-530; Ganapathy-Kanniappan and Geschwind (2013) Mol.Cancer 12:152). 3-Bromopyruvate (3-BrPA), a highly potent small molecule inhibitor of the enzyme glyceraldehyde phosphate-3-dehydrogenase (GAPDH), is the only available anti-glycolytic drug candidate that is able to selectively enter cancer cells via the monocarboxylate transporter 1 (MCT1) (Ganapathy-Kanniappan et al. (2009) AntiCancer Res. 29:4909-4918; Birsoy et al. (2013) Nature Genet.45:104-108). The anti-tumor effects of 3-BrPA have been extensively studied and confirmed in several murine tumor models in the setting of locoregional therapy, either delivered via tumor-feeding arteries or direct intratumoral injection (Ota et al. (2013) Target. Oncol. 8:145-151; Geschwind et al. (2002) Canc. Res. However, due to its alkylating properties, 3-BrPA has been shown to have significant toxicity when delivered systemically at therapeutic doses, which in turn may hinder the clinical development and use of this drug in cancer patients (Chang et al. (2007) Acad. Radiol. 14:85-92; Cao et al. (2008) Clin. Canc. Res. 14:1831-1839).

[0191] A. Antibodies, Reagents, and Kits

[0192] The following primary antibodies were used: rabbit anti-MMP-9 polyclonal antibody (pAB) #3852 (Cell Signaling), DAPI #D1306 (Invitrogen), Alexa Fluor 568 Phalloidin #12380 (LifeTechnologies), GAPDH (14C10) monoclonal AB (mAB) Alexa Fluor 488 conjugate #3906 (CellSignaling), GAPDH pAB #sc-47724 (Santa Cruz), cleaved caspase-3 pAB #9661 (CellSignaling), MCT-1 pAB #sc50324 (Santa Cruz), and Ki-67 kit / antibody (Dako Inc.). The following secondary antibodies were used: goat anti-rabbit IgG HRP-conjugated #7074 (Santa Cruz), anti-rabbit IgG (H+L), F(ab')2 fragment PE conjugate #8885 (Cell Signaling), and goat anti-mouse IgG-FITC #sc2010. The following chemicals were used: 3-bromopyruvic acid (3-BrPA, Sigma Aldrich), gemcitabine hydrochloride (LC Laboratories), succinyl-β-cyclodextrin (β-CD, Sigma Aldrich), and D-luciferin potassium salt (Gold Biotechnology, StLouis, MO, USA). The following cell culture reagents were used: RPMI-1640 (Life Technologies), MEM (Life Technologies), fetal bovine serum (FBS, Thermo Scientific), penicillin / streptomycin (Sigma Aldrich), collagen I rat tail (BD Biosciences, #354326), and a controlled atmosphere chamber (Plas. Labs). The following invasive assay reagents were used: Matrigel basement membrane matrix (BD Biosciences) and Matrigel invasion chamber transwell polycarbonate membrane inserts (Corning). The following kits were used: CellTiter-Glo luminescent cell viability assay kit (Promega), dual luciferase reporter assay kit (Promega), 2D quantification kit (GE Healthcare), histostain plus 3rd gen ICH detection kit (Invitrogen), and diff quik staining kit (Polysciences Inc.).The following imaging equipment was used: Zeiss 700 LSM confocal microscope, Olympus IX81 inverted microscope, Eclipse TS100 inverted microscope (Nikon), and IVIS200 (Xenogen Corp., Alameda, CA).

[0193] B. Complex Preparation and Nuclear Magnetic Resonance (NMR) Spectroscopy

[0194] To prepare 3-BrPA encapsulated in β-CD, 3-BrPA (166 mg, 1 mM) was added in small portions (10 mg each) to a stirred solution of β-CD (918 mg in 20 ml DI water). After the addition was complete, the solution was sonicated at 50°C for 1 hour. The sonicated solution was then allowed to shake overnight at 25°C in a thermomixer, flash frozen in a dry ice-acetone bath and lyophilized. The lyophilized complex was used as is for further biological and biophysical studies. 1 H NMR experiments were performed on a Bruker Avance spectrometer at 400 MHz. NMR spectra were recorded in 99.9% D2O and reported in parts per million downfield relative to tetramethylsilane (TMS). 10 mM solutions of β-CD alone, 3-BrPA alone, or 3-BrPA and β-CD complex were prepared with 1% DSS (3-(trimethylsilyl)-1-propanesulfonic acid, sodium salt; SigmaAldrich) as internal standard. Spectra were recorded at 25 °C with 32 scans. An upfield shift of the methylene protons (0.1 ppm) was observed upon complexation (see Figure 7 ).

[0195] C. Monolayer Cell Culture and Viability Assays

[0196] Two human pancreatic adenocarcinoma cell lines, lucMiaPaCa-2 (stable transfection with luciferase-aminoglycoside phosphotransferase fusion gene, kindly provided by Dr. Phuoc T. Tran) and Suit-2 (kindly provided by Dr. Shinichi Ota, Japan) were cultured in RPMI or MEM medium, respectively, supplemented with 10% FBS and 1% penicillin-streptomycin. The effect of different drugs on cell viability was determined by quantifying intracellular adenosine triphosphate (ATP) levels using a luminescence-based kit (CellTiter-Glo, Promega) and multi-label 96-well plates (Costar). The accuracy and reproducibility of viability measurements in lucMiaPaCa-2 cells using this fluorescence-based kit were confirmed using a dual-luciferase reporter assay kit (Promega). Briefly, 5 x 10 3 Cells were seeded in triplicate and cultured for 72 h under normoxic or hypoxic conditions (1% O2-level, balanced with CO2 and nitrogen in a controlled atmosphere chamber). The indicated amounts of free 3-BrPA, 1:1-β-CD-3-BrPA, or β-CD as a control were dissolved in PBS and added to the culture medium for 24 h. For experiments with gemcitabine, cells were cultured for 24 h before exposure to the drug for 72 h. Cell viability was determined according to the manufacturer's protocol.

[0197] D. 3D organotypic cell culture, imaging, and immunofluorescence

[0198] Collagen 1-based 3D organotypic cell cultures were used to simulate an extracellular matrix (ECM)-rich environment and test the effect of 3-BrPA on tumor invasiveness (Cheung et al. (2013) Cell 155:1639-1651; Nguyen-Ngoc and Ewald (2013) J. Microscop. 251:212-223). Specifically, a collagen solution initially consisting of 25 µl 10x DMEM and 217 µl collagen I (3.83 mg / ml) was prepared on ice. The pH was adjusted by dropwise addition of sodium hydroxide (Sigma Aldrich) to pH = 7.0. Collagen I was then diluted to a final concentration of 3 mg / ml using DMEM F12 / GlutaMAX (LifeTechnologies). A bottom layer was created using 15 µl of the collagen solution in the bottom of each well of a 24-well glass-bottomed plate without a lid (InVitroScientific), which was then allowed to polymerize at 37°C for at least 1 hr. The remaining collagen solution was kept on ice for 3-5 hours to allow initial polymerization. A total of 65 x 10 3 lucMiaPaCa-2 or 45 x 10 3 Suit-2 cells were resuspended in a 150 µl volume of collagen solution. The cell suspension was placed on top of the pre-heated lower layer by creating a drop of 0.5 cm height. The collagen-cell suspension was allowed to polymerize at 37°C for 1 h and then covered with cell culture medium (Nguyen-Ngoc and Ewald (2013) J. Microscope. 251:212-223).

[0199] 3D organelles were treated either once or sequentially. For single treatments, embedded cells were cultured for 5 days under normoxic or hypoxic (1% O2-level in a controlled atmosphere chamber) conditions before treatment. On day 5, the culture medium was replaced with a medium containing 1:1-β-CD-3-BrPA / 3-BrPA / β-CD, and the cells were cultured with the drugs at various concentrations for 24 hours. For experiments with gemcitabine, cells were grown for 48 hours before treatment and cultured with the drugs for another 72 hours. Initial experiments with gemcitabine did not show any efficacy after 24 hours, so it was decided to follow the most commonly reported culture time of 72 hours. Continuous treatments with 3-BrPA were performed every other day with the respective doses, continued for 1 week and evaluated with a bright field microscope (Olympus) at 40x magnification with a 1.3 NA oil eyepiece. Images were acquired using a Hamamatsu Photonics C9100-02 EMCCD camera with the SlideBook 5.0 program.

[0200] Microscope observation is compared with the quantification of cell viability as seen on in vitro bioluminescent imaging (BLI).For the latter measurement, the cell culture medium covering the 3D organotypic cell culture is replaced with 500 ul luciferase substrate (D-luciferin, potassium salt, Life Technologies, 20 mg / ml) in PBS.After exposure for 5 minutes, the plate is positioned and image is collected (Xenogen Ivis Imaging System 100).Signal intensity (counting) is determined by photon emission and measured in the region of interest (ROI) of the whole 3D organelle (Living Image Software, PerkinElmer).

[0201] Immunofluorescence microscopy was used to verify the microscopic and BLI results. 3D organelles were fixed with 4% formaldehyde and cryofixed with OCT compound (Tissue Tek) at -80°C. Samples were cut into 100 µm thick sections at -20°C. OCT was washed twice with PBS for 10 mins each. Before staining, sections were permeabilized with 0.5 % Trizol 100 in PBS for 30 mins and washed twice with PBS for 10 mins each. After blocking with 10% FBS in PBS for 2 h, samples were incubated with primary antibodies (Alexa Fluor 568 phalloidin, Invitrogen, 1:100; GAPDH Alexa Fluor 488 conjugate, CellSignalling, 1:800; cleaved caspase-3, Cell Signalling, 1:500; HIF-1 α 1:50) at room temperature (RT) for 1 hr under light protection. For non-conjugated primary antibodies, additional incubations with phycoerythrin (PE)- or fluorescein isothiocyanate (FITC)-conjugated secondary antibodies were also used at RT for 1 hour. This was followed by two washes with PBS for 10 mins each. DAPI was used as a counterstain at a concentration of 300 ng / ml and added to the sample simultaneously with the conjugated antibody. The sample was sealed with an antifading mountant and covered with a coverslip. Confocal fluorescence microscopy was performed at 40x magnification with a 1.4 NA oil eyepiece and 63x magnification with a 1.4 NA oil eyepiece. Images were analyzed with Zen 2012 software (Carl Zeiss). Excitation and emission wavelengths were those recommended by the conjugate manufacturer. For example, 555 nm is used to excite phalloidin and PE-conjugates, 488 nm is used to excite Alexa Fluor 488, and FITC-conjugates, and 405 nm is used to excite DAPI. Emission is checked between 555 and 1000 nm for red fluorescence, and 490 nm and above for green fluorescence. DAPI emission is captured below 490 nm or below 529 nm when imaging with red or green fluorescence, respectively.

[0202] E. Matrigel invasion assay, zymography, and immunoblotting

[0203] The ability of 3-BrPA to inhibit tumor invasion was investigated using a Matrigel invasion assay, as well as gelatin zymography (Hu and Beeton (2010) J. Visual. Exp. 45:2445; Scott et al. (2011) J. Visual. Exp.58:e3525). For the Matrigel invasion assay, a coating buffer containing 0.01 M Tris and 0.7% NaCl was prepared and used to dilute Matrigel Basement Membrane (BD Biosciences, #356234) to 300 ug / ml. Subsequently, Boyden chambers (Transwell, Corning; 6.5 mm-diameter, 8 um pore size) were coated with 100 µl of Matrigel solution and stored at 37°C for 2 hours to allow gelation. Approximately 7.5 x 10 4 The cells were resuspended in 500 μl of FBS-free medium and plated in the upper chamber of the insert, which was then placed in a 24-well plate containing 750 μl of medium containing FBS. After culturing overnight at 37°C, different amounts of 3-BrPA dissolved in PBS were added to the upper chamber. After 48 hours, non-invasive cells were removed from the matrix gel with a cotton swab. The invaded cells adhered to the bottom side of the permeable insert were fixed and stained with a Diff Quik staining kit (Polysciences Inc.). Light microscopy was performed using a colored inverted microscope (Eclipse TS 100) at 4x, 10x, and 20x magnifications. By measuring the area of ​​stained cells after treatment at 10x magnification, the invasion of cells was quantified compared with untreated samples.

[0204] Zymography was performed to measure the activity of secreted MMP-9. 6 Suit-2 cells and 2.5 x10 6 luc MiaPaCa-2 cells were seeded in 75 cm 2-flask and cultured overnight at 37°C under normoxic conditions. The next day, fresh FBS-free culture medium containing different concentrations of 3-BrPA was added and the cells were cultured for another 24 hours. Subsequently, the supernatant was collected, filtered, and the final protein concentration was determined using a 2D Quant kit (GE Healthcare). After adjusting the concentration, each sample was loaded into two 10% gelatin zymography gels (Novex, Invitrogen). After electrophoresis, the protein in one of the two gels was renatured and allowed to be enzymatically digested overnight at 37°C in a developing buffer. The gel was stained with 4 parts of 0.1% Coomassie Brilliant Blue in 1 part of 100% methanol for 24 hours and washed with dilute (DI) water until the digested area was detected as a white band. Western blot analysis was performed using duplicate gels. Proteins were blotted onto PVDF-membranes and blocked using 5% skim milk in 1x TBS and 0.1% Tween / DI (TBST). Primary anti-MMP antibodies (Cell Signaling) were used at a 1:1000 dilution and incubated overnight at 4°C, followed by HRP-conjugated secondary antibodies (Santa Cruz) for 1 hr at room temperature. HRP provides an electrochemiluminescent signal (ECL Kit, GE Healthcare), which was analyzed with ImageJ 1.46r software (Wayne Rasband, National Institute of Health) and used to quantify signal intensity by comparing line integrals.

[0205] F. Orthotopic Animal Xenografts

[0206] Male athymic nude mice (body weight, 20-25 g; 4 weeks old; Crl:NU (NCr)-Foxn1 nu ; Charles River Laboratory, Germantown, MD, USA). Mice were maintained in a laminar flow chamber at a constant temperature and humidity with free access to food and water. 6 lucMiaPaCa-2 was injected into the tail of the pancreas of anesthetized mice to generate orthotopic xenograft tumors. To do this, mice were placed in a clean anesthesia induction chamber (oxygen flow rate, 1 L / min; isoflurane concentration, 3-4%). ​​After loss of the righting reflex, the animal was placed on the surgical table, where a nose cone was used to maintain anesthesia (oxygen flow, 0.8 L / min; isoflurane concentration, 1.5-2%). A small, left ventral incision was made, and the pancreas was exteriorized for injection of the cell solution using a 30G Hamilton syringe. Successful subcapsular intrapancreatic injection was identified by the appearance of fluid blisters without intraperitoneal leakage. The peritoneal cavity was sutured with a double layer of non-absorbable suture material (Kim et al. (2009) Nat. Protocol. 4:1670-1680).

[0207] G. Bioluminescence imaging and ultrasound imaging

[0208] Tumor viability was confirmed by in vivo bioluminescence imaging (BLI) on the 7th day after surgical implantation. Anesthetized tumor-bearing mice were injected intraperitoneally with D-luciferin 150 mg / kg and optically imaged using the IVIS 200 system (Xenogen) 5 minutes later. Pseudo-color images representing the spatial distribution of photons were superimposed on previously acquired grayscale photographic images. Regions of interest (ROIs) were created to include optical tumor images. After 10-second exposure, the signal intensity was quantified in ROI in photons / second / square centimeter / steradian (p / s / cm2 / Sr) using Living Image software (Xenogen). Additionally, after treatment with small-animal ultrasound imaging (USI), the in situ growth of the tumor was confirmed. Briefly, anesthetized mice were examined using a VEVO2100 (VisualSonics Inc., Toronto, Canada, kindly provided by Dr. Harry C. Dietz) using a 40 MHz MS-550D MicroScan transducer probe (with a broadband of 22-55 MHz). Tumor localization was confirmed using the apex of the left kidney and the caudal tip of the spleen as anatomical landmarks (Ota et al. (2013) Target. Oncol. 8:145-151; Tuli et al. (2012) Translat. Oncol. 5:77-84).

[0209] H. Treatment options and follow-up imaging

[0210] Animals bearing tumors, as confirmed by both LI and USI, were randomized into 4 groups: Group 1 (N = 21 animals) received daily intraperitoneal injections of β-CD-3-BrPA complex (5 mg / kg 3-BrPA in 26 mg / kg β-CD in 500 µl saline at a 1:1 molar ratio) and Group 2 (N = 7 animals) received intraperitoneal injections of gemcitabine (150 mg / kg in 200 µl saline, 3 injections / week, as generally reported in the literature, e.g., Liau and Whang (2008) Clin. Canc. Res. 14:1470-1477; Larbouret et al. (2010) Annal. Oncol. 21:98-103), group 3 (N = 7) received daily intraperitoneal injections of β-CD (26 mg / kg β-CD in 500 µl saline), and group 4 (N = 7 animals) received daily intraperitoneal injections of 3-BrPA alone (5 mg / kg in 500 µl saline). All animals were treated uninterrupted for four weeks. BLI was collected on days 7, 14, 21, and 28 after the first injection. Animals were sacrificed on day 28 after the last imaging period or when moribund.

[0211] I. Immunohistochemistry

[0212] After sacrificing the animals, the tumors were harvested, fixed with 4% formaldehyde solution for a period of at least 72 hours, and embedded in paraffin for immunohistochemical analysis. Hematoxylin and eosin (H&E) staining of slides followed standard protocols, such as those described in Casadonte and Caprioli (2011). ) Nat. Protocol.6:1695-1709. Tumor sections 18 μm thick were stained for the following purposes: GAPDH, MCT-1, cleaved caspase-3, and Ki-67 were detected using Histostain plus third-generation Gen IHC detection kit (Invitrogen), and Ki-67 kit (Dako Inc.). In particular, samples were dewaxed using xylene and rehydrated using a reduced ethanol dilution series. After washing with deionized water, the samples were infiltrated in a boiling recovery solution containing citric acid (Dako) at 95° for 40 minutes. The samples were cooled to RT and incubated with 2 drops (total ~100 ul) of peroxidase quenching solution for 5 min, and blocked for 20 mins. Incubation with primary antibodies (GAPDH, 1:500; MCT-1, 1:250; Ki-67 and HIF-1α; 1:50, cleaved caspase-3, 1:1,500; in PBS) occurred at RT in a humidified chamber for 60 mins. Biotinylated secondary antibodies and streptavidin-peroxidase conjugate were added to the samples sequentially for 10 min each. 26.5 ul of 3,3'-diaminobenzidine (DAB) chromogen was mixed thoroughly with 1 ml of DAB substrate buffer and 100 ul was added to each sample over 5 mins. Hematoxylin was used as a counterstain. The incubation step was followed by washing with distilled water and twice with PBS for 2 mins each. Samples were sealed with antifading mountant and covered with coverslips. All slides were scanned and imaged at 20x magnification using a high-resolution Aperio ® Scanning system (Vista, California, USA) digitized. Then, Aperio imager ® Software (Aperio ImageScope ® For Ki-67-stained tissue sections, a total of 5-10 fields of view were observed at 10x, and the number of Ki-67-positive cells and the total number of cells were recorded to calculate the Ki-67 labeling index (formula: index [%] = [number of positive cells / total number of cells r] x 100).

[0213] J. Statistical data analysis

[0214] All experiments were performed independently and repeated at least 3 times. Data from the experiments were summarized with mean ± standard error of the mean. Statistical comparisons of data sets were performed using Student's t-test and one-way ANOVA. The BLI signal intensities reported in animals were normalized and reported as multiples based on baseline values.

[0215] Example 5: β-CD-3-BrPA shows strong anti-cancer effects in 2D and 3D cell culture and targets metabolism to reduce the invasive potential of cancer cells

[0216] The complex between 3-BrPA and β-CD was confirmed by NMR spectroscopy. Figure 7 ), the microencapsulated formulation of the drug was used for further experiments. To evaluate the efficacy of microencapsulated 3-BrPA (β-CD-3-BrPA) in achieving dose-dependent ATP depletion and cell death, two human pancreatic cancer cell lines were used. MiaPaCa-2 was derived from primary pancreatic adenocarcinoma (PDAC) and Suit-2 was derived from metastatic primary pancreatic adenocarcinoma of different patients (Kitamura et al. (2000) Clin. Exp. Metast. 18:561-571). The dose-dependent effects of β-CD-3-BrPA were compared with free 3-BrPA and gemcitabine, while β-CD was used as a control. As hypoxia is often associated with chemoresistance in PDAC, hypoxic exposure was added to the experimental design (Yokoi and Fidler (2004) Clin. Canc. Res. 10:2299-2306; Kasuya et al. (2011) Oncol. Rep. 26:1399-1406; Onozuka et al. (2011) Canc. Sci. 102:975-982; Zhao et al. (2014) Canc. Res. 74:2455-2464)). It was found that β-CD-3-BrPA and free 3-BrPA displayed similar cytotoxicity profiles under normoxic (50-75 µM) and hypoxic (12.5-25 µM) conditions and, interestingly, were more sensitive to the drug under hypoxic conditions ( Figure 8 ). Cell lines treated with β-CD alone were completely viable throughout the experiment, even when exposed to extremely high concentrations. Similar results were observed for Suit-2 cells, but the differences between normoxic and hypoxic conditions were less pronounced ( Figure 8 When evaluating the efficacy of gemcitabine, the IC 50 No concentration achieved complete killing under normoxic conditions (0.1 µM) was barely achievable, and hypoxia appeared to increase resistance to the drug.

[0217] To test the efficacy of β-CD-3-BrPA in an ECM-rich environment, luc MiaPaCa-2 cells were cultured in 3D collagen 1 matrices and treated with a single dose of β-CD-3-BrPA, free 3-BrPA, or β-CD (as a control). BLI quantification showed that both drug preparations increased in normoxic conditions (IC 50, 25-50 µM) had equivalent potency ( Figure 8 ). Under hypoxic conditions, MiaPaCa-2 cells were slightly more sensitive to free 3-BrPA than to β-CD-3-BrPA ( Figure 8 Cells cultured in 3D were subsequently treated with drugs as described in Example 4. Morphological, BLI, and immunofluorescence-based analyses confirmed the ability of 3-BrPA to penetrate the ECM-rich matrix and inhibit cell proliferation, as well as induce apoptosis ( Figure 9-10 ), whereby untreated MiaPaCa-2 cells proliferated within the collagen 1 matrix and formed “grape”-like structures, whereas Suit-2 cells displayed a more invasive growth pattern with visible cell processes after 6 days of growth ( Fig.10 When treated with 3-BrPA, proliferation of both cell lines was inhibited, with a significant reduction in cell processes in Suit-2 cells ( Fig.10 ). In addition, immunofluorescence imaging confirmed the dose-dependent induction of cell apoptosis by 3-BrPA.

[0218] In addition, the ability of 3-BrPA to inhibit the invasiveness of pancreatic cancer cells at sub-lethal drug concentrations was examined using a matrigel invasion assay. Fig.11 As shown in A-11B, both locally invasive MiaPaCa-2 cells and metastatic Suit-2 cells showed reduced invasiveness at drug concentrations as low as 12.5 µM. In addition, the effect of sub-lethal doses of 3-BrPA on the secretion of matrix-metalloproteinase 9 (MMP-9), a well-described marker for the invasive potential of pancreatic cancer cells, was examined using gelatin zymography and immunoblotting (Jones et al. (1999) Annal. NY Acad. Sci. 880:288-307; Merdad et al. (2014) Anticanc. Res. 34:1355-1366; Yang et al. (2001) J. Surg. Res. 98:33-39). Thus, a significant reduction in MMP-9 secretion was detected in both cell lines. This effect was observed starting with a concentration of 6.25 µM 3-BrPA, a dose that does not induce apoptosis or reduce cell viability, and occurred earlier in the more metastatic Suit-2 cell line ( Fig.11 C-11D).

[0219] Example 6: Systemic delivery of β-CD-3-BrPA achieves strong anti-cancer effects in vivo

[0220] The anti-cancer effect of systemically delivered β-CD-3-BrPA was examined in athymic nude mice using a xenograft model of human pancreatic cancer. Before selecting a therapeutic dose for more detailed studies, a comparative dose escalation study in non-tumor bearing animals was performed for both β-CD-3-BrPA and free 3-BrPA. Thus, after a single injection, 20 mg / kg β-CD-3-BrPA and 10 mg / kg free 3-BrPA were determined to be the median lethal dose (LD50). 50 ), and 5 mg / kg β-CD-3-BrPA was determined to be a safe dose without causing any toxicity when administered systemically and once daily for a 7-day course of treatment. A total of 42 animals with orthotopically-implanted and BLI- and USI-confirmed MiaPaCa-2 tumors were then randomized to receive intraperitoneal (ip) injections of β-CD-3-BrPA (N = 21), gemcitabine (N = 7), or β-CD (N = 7). Another group of animals with orthotopic implants (N = 7) were treated with free 3-BrPA. Animals treated with daily intraperitoneal (ip) injections of free 3-BrPA (5 mg / kg in 500 µl saline) showed high treatment-related toxicity and 3 / 7 (43%) animals died before the first follow-up BLI was collected ( Fig.12 C). At the end of the experiment (day 28), only 2 / 7 (28%) of the animals treated with free drug were still alive ( Fig.12 C). Such mortality was not observed in any of the remaining groups. Daily ip injections of β-CD-3-BrPA (5 mg / kg in 500 µl saline) showed a strong anti-cancer effect, with early effects visible on day 14 after the first injection ( Fig.12 B). After 4 weeks of treatment, BLI signal intensity was compared between groups. Animals treated with β-CD control exhibited a 140-fold signal increase compared to baseline. A modest slowing of tumor growth was observed in gemcitabine-treated animals, with a 60-fold increase in signal over time. Most importantly, animals treated with β-CD-3-BrPA showed minimal or no signal progression compared to gemcitabine and control groups ( Fig.12 After reaching this endpoint, animals were sacrificed and tumors were harvested for further analysis. All animals underwent necropsy and organs (brain, heart, lung, intestine, liver, and kidney) were harvested for analysis of potential tissue damage. No organ toxicity or tissue damage was observed in animals treated with β-CD-3-BrPA ( Fig.12 D) Pathological analysis of tumors in animals treated with β-CD-3-BrPA showed very extensive tumor destruction with central areas of liquefactive necrosis ( Fig.13). Tumor areas with intact cell junctions showed high expression of cleaved caspase-3, indicative of fulminant tumor cell apoptosis. Animals treated with β-CD-3-BrPA showed a significant reduction in proliferation, as assessed by Ki67 immunohistochemistry with a mean of 17% and 51%, respectively ( Fig.13 ). In addition, animals treated with β-CD-3-BrPA showed lower expression levels of MCT1 and GAPDH within treated tumors compared with the β-CD or gemcitabine groups.

[0221] These results indicate that systemically delivered β-CD-3-BrPA achieves a strong anti-tumor effect in vivo while causing much less toxicity at therapeutic doses when compared to the free drug. Furthermore, microencapsulated 3-BrPA does not alter the drug's efficacy against pancreatic cancer cells in vitro, as demonstrated using 2D, as well as ECM-enriched 3D cell cultures under both normoxic and hypoxic conditions. The ability of 3-BrPA to inhibit the secretion of MMP-9 and reduce the invasiveness of pancreatic cancer cells at sublethal doses also indicates an anti-metastatic potential of this drug.

[0222] Selectively targeting tumor metabolism has long been considered an ideal therapeutic option but has yet to be translated into clinical practice. The main limitation in achieving systemic delivery capabilities using 3-BrPA is the reported toxicity due to its alkylating properties (Ganapathy-Kanniappan and Geschwind (2013) Mol.Cancer 12:152; Chang et al. (2007) Acad. Radiol. 14:85-92; Kunjithapatham et al. (2013) BMC Res. Not. 6:277). As a result, local image-guided drug delivery has been explored as an alternative treatment option; however, the practical application of these approaches is limited to the treatment of localized diseases (Ota et al. (2013) Target. Oncol. 8:145-151; Geschwind et al. (2002) Canc. Res. 62:3909-3913). The results described herein clearly demonstrate that the drug, when properly formulated for systemic delivery, is extremely effective, thereby expanding the application of this compound to virtually any cancer. These results contrast with those of other studies in which the drug was used systemically only in its free form to treat solid tumors. In that study, free 3-BrPA failed to induce any meaningful tumor response at the doses used in the experiments described herein (Cao et al. (2008) Clin. Canc. Res. 14:1831-1839; Schaefer et al. (2012) Translat. Res.159:51-57). In particular, a study that explored the systemic delivery of free 3-BrPA in combination with an HSP90 inhibitor in subcutaneous pancreatic cancer xenografts did not report any significant effect when 3-BrPA was used alone at a dose of 5 mg / kg (administered twice weekly for safety reasons) (Cao et al. (2008) Clin. Canc. Res. 14:1831-1839). One possible explanation for this adverse therapeutic profile of the free drug is the rapid activation of 3-BrPA through nonspecific interactions with serum proteins, which is known to occur in vivo as early as 2-3 minutes after systemic administration (Kunjithapatham et al. (2013) BMC Res. Not. 6:277). Some efficacy was observed at these doses, but excessive toxicity, with treatment-related deaths in the majority of animals, was the predominant outcome. Therefore, it is believed that systemic administration of free 3-BrPA may not be effective and may increase unwanted toxicity. It is also believed that in the microencapsulated formulation, 3-BrPA is more bioavailable for uptake into tumor cells and less available to normal cells which may significantly mediate its toxicity (Birsoy et al. (2013) Nature Genet. 45:104-108; Zhang and Ma (2013) Advanc. Drug Deliv. Rev. 65:1215-1233; Heidel and Schluep (2012) J. Drug Deliv. 2012:262731).

[0223] A characteristic of pancreatic tumor tissue is the excessive accumulation of dense ECM, which limits the diffusion of oxygen and creates a highly hypoxic, poorly perfused tumor microenvironment that is responsible for its remarkable chemoresistance and increased invasiveness (Yokoi and Fidler (2004) Clin. Canc. Res. 10:2299-2306; Yang et al. (2001) J. Surg. Res. 98:33-39). Published studies have demonstrated that more than 30% of pancreatic tumor cells reside in the hypoxic tumor compartment, thereby circumventing the effects of traditional chemotherapy. These cells then go on to reform a tumor that becomes even more aggressive and resistant to chemotherapy (Guillaumond et al. (2013) Proc. Natl. Acad. Sci. USA 110:3919-3924). The results described herein indicate that 3-BrPA is able to effectively block tumor glycolysis even when it is exacerbated under hypoxic conditions. In contrast, gemcitabine, even at the highest dose, has been shown to be incapable of coping with hypoxia in pancreatic cancer cells. So far, conflicting data have been reported on the oxygen dependency of 3-BrPA in cancer cells (Cao et al. (2008) Canc. Chemother. Pharmacol.62:985-994; Xiao et al. (2013) Oncol. Rep. 29:329-334). However, there is significant evidence supporting the ability of 3-BrPA to overcome hypoxia as a key mechanism of resistance (Xu et al. (2005) Canc. Res. 65:613-621). In particular, recent studies have established a link between hypoxia and expression of MCT-1, which was shown to be overexpressed in hypoxic cells and tumor regions, thus providing a functional explanation for the increased sensitivity of hypoxic tumor tissues to 3-BrPA (Matsumoto et al. (2013) Magnet. Res. Med. 69:1443-1450). Of note, combining gemcitabine and 3-BrPA has been explored in vitro to effectively achieve an increase in therapeutic efficacy; however, the combination effect was not identified and, therefore, the respective in vivo experiments were not performed.

[0224] Furthermore, using collagen 1-rich 3D organotypic cell cultures as a model of an ECM-rich tumor microenvironment, it has been demonstrated that 3-BrPA has the ability to successfully penetrate the matrix without any measurable reduction in efficacy compared to monolayer cell cultures. The 3D cell culture model used for the studies described herein can be considered relatively specific, primarily because it is composed of a matrix that mimics the collagen 1-rich ECM as seen in human ex vivo samples (Mollenhauer et al. (1987) Pancreas 2:14-24). Although the benefits of such in vitro models are increasingly recognized for the purpose of drug testing, simulating these conditions in vivo represents a greater challenge (Longati et al. (2013) BMC Canc. 13:95). When designing such studies, different animal models should be considered. On the one hand, the use of widely accepted orthotopic xenograft models offers important advantages, such as reproducibility, predictable tumor growth kinetics, and allows for genomic modification of tumor cells to express specific and imageable reporter genes (Kim et al. (2009) Nat. Protocol. 4: 1670-1680). On the other hand, the extent to which these models reflect the tumor microenvironment in human lesions is unclear. Although several well-defined mouse tumor models are able to simulate ECM-compositions and tumor hypoxia more realistically, these models seem less suitable for the purpose of standardized drug testing (Guillaumond et al. (2013) Proc. Natl. Acad. Sci. USA110:3919-3924). In order to demonstrate the ability of 3-BrPA to inhibit cell invasiveness in vitro, the use of the metastatic Suit-2 xenograft model was considered. However, orthotopic implantation of Suit-2 xenografts resulted in complications (i.e., bloody ascites) and loss of most animals within 14 days post-implantation, which prompted the selection of MiaPaCa-2 xenografts as a viable alternative.

[0225] An additional unexpected result was observed in the immunohistochemical analysis of treated tumor tissues: following the expected and previously reported depletion of GAPDH as a molecular target of 3-BrPA, the amount of MCT-1, a specific transporter for 3-BrPA, was significantly reduced in the treated samples (Ganapathy-Kanniappan et al. (2012) Radiol. 262:834-845). To date, no evidence exists for the existence of MCT-1 as a potential target of 3-BrPA. However, this lactate transporter has been repeatedly identified as a suitable molecular target for cancer therapy (Schneiderhan et al. (2009) Gut 58:1391-1398; Shih et al. (2012) Oncotarget 3:1401-1415; Sonveaux et al. (2012) PloS One 7:e33418).

[0226] Thus, the results described herein identify microencapsulated 3-BrPA as a promising advance toward the ultimate goal of systemically delivered anti-glycolytic tumor therapies. The potent anti-cancer effects and favorable toxicity profile of β-CD-3-BrPA pave the way toward clinical trials in patients with pancreatic cancer and potentially other malignancies.

[0227] Combined by reference

[0228] The contents of all references, patent applications, patents, and published patent applications cited throughout this application, as well as the figures and sequence listing are incorporated herein by reference. It should be understood that although many patent applications, patents, and other references are cited herein, such references do not constitute an admission that any of these documents form part of the common general knowledge in the art.

[0229] Equivalent solution

[0230] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

1. A composition comprising β-cyclodextrin and a drug, wherein the drug is 3-halopyruvic acid, wherein at least one α-D-pyranoglucoside unit of the cyclodextrin has at least one hydroxyl chemical group replaced with an ionizable chemical group, the ionizable chemical group is a succinyl group, and wherein the cyclodextrin encapsulates the drug.

2. The composition of claim 1, wherein at least one hydroxyl chemical group of the at least one α-D-glucopyranoside unit is selected from the group consisting of C2, C3 and C6 hydroxyl chemical groups.

3. The composition of claim 1, wherein the C2, C3 and C6 hydroxyl chemical groups of at least one α-D-glucopyranoside unit of the cyclodextrin are replaced with succinyl groups.

4. The composition of any one of claims 1 to 3, wherein the at least one α-D-pyranoside unit of the cyclodextrin is selected from 2, 3, 4, 5, 6, 7, 8 and all α-D-pyranoside units of the cyclodextrin.

5. The composition of any one of claims 1-3, wherein the composition is a liquid or solid pharmaceutical preparation.

6. The composition of any one of claims 1-3, wherein the drug is uncharged or hydrophobic.

7. The composition of any one of claims 1-3, wherein the drug is 3-bromopyruvic acid.

8. The composition of any one of claims 1-3, wherein the composition is formulated for systemic administration.

9. The composition of any one of claims 1-3, further comprising an anti-cancer therapeutic agent.

10. A kit comprising the composition of any one of claims 1 to 9, and instructions for use.

11. Use of the composition of any one of claims 1-9 in the manufacture of a medicament for treating a subject suffering from cancer, wherein the composition is administered to the subject in a therapeutically effective amount.

12. The use according to claim 11, wherein the composition is administered systemically.

13. The use according to claim 12, wherein the systemic administration is selected from the group consisting of oral, intravenous, intraperitoneal, subcutaneous and intramuscular administration.

14. The use of any one of claims 11-13, wherein the subject is treated with at least one additional anti-cancer therapy.

15. The use of claim 14, wherein the at least one additional anti-cancer therapy is radiation therapy.

16. The use of any one of claims 11-13, wherein the cancer is a solid tumor.

17. The use according to any one of claims 11 to 13, wherein the cancer is selected from liver cancer, pancreatic cancer, lung cancer and breast cancer.

18. The use according to claim 17, wherein the cancer is liver cancer.

19. The use of any one of claims 11-13, wherein the subject is a mammal.

20. The use of claim 19, wherein the mammal is a human.